{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:02:24Z","timestamp":1789394544780,"version":"build-2803163510"},"reference-count":458,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lilian Sagen and Curt Ericsson Research Foundation"},{"DOI":"10.13039\/501100003748","name":"Svenska S\u00e4llskapet f\u00f6r Medicinsk Forskning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003748","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006313","name":"Barncancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007232","name":"Radiumhemmets Forskningsfonder","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40259-026-00798-6","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:35:43Z","timestamp":1788338143000},"page":"821-867","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting MYC-Driven Cancers: From Oncogenic Addiction to Therapeutic Vulnerability"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9406-6478","authenticated-orcid":false,"given":"Lourdes","family":"Sainero-Alcolado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8603-9368","authenticated-orcid":false,"given":"Dilraj","family":"Lama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5514-8625","authenticated-orcid":false,"given":"Mohammad","family":"Alzrigat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6376-7792","authenticated-orcid":false,"given":"Marie","family":"Arsenian-Henriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"issue":"2","key":"798_CR1","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1128\/jvi.28.2.600-610.1978","volume":"28","author":"D Sheiness","year":"1978","unstructured":"Sheiness D, Fanshier L, Bishop JM. Identification of nucleotide sequences which may encode the oncogenic capacity of avian retrovirus MC29. J Virol. 1978;28(2):600\u201310. https:\/\/doi.org\/10.1128\/jvi.28.2.600-610.1978.","journal-title":"J Virol"},{"issue":"2","key":"798_CR2","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1128\/jvi.31.2.514-521.1979","volume":"31","author":"D Sheiness","year":"1979","unstructured":"Sheiness D, Bishop JM. DNA and RNA from uninfected vertebrate cells contain nucleotide sequences related to the putative transforming gene of avian myelocytomatosis virus. J Virol. 1979;31(2):514\u201321. https:\/\/doi.org\/10.1128\/jvi.31.2.514-521.1979.","journal-title":"J Virol"},{"issue":"3","key":"798_CR3","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1128\/jvi.42.3.773-779.1982","volume":"42","author":"B Vennstrom","year":"1982","unstructured":"Vennstrom B, Sheiness D, Zabielski J, Bishop JM. Isolation and characterization of c-myc, a cellular homolog of the oncogene (v-myc) of avian myelocytomatosis virus strain 29. J Virol. 1982;42(3):773\u20139. https:\/\/doi.org\/10.1128\/jvi.42.3.773-779.1982.","journal-title":"J Virol"},{"issue":"24","key":"798_CR4","doi-asserted-by":"publisher","first-page":"7824","DOI":"10.1073\/pnas.79.24.7824","volume":"79","author":"R Dalla-Favera","year":"1982","unstructured":"Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA. 1982;79(24):7824\u20137. https:\/\/doi.org\/10.1073\/pnas.79.24.7824.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"24","key":"798_CR5","doi-asserted-by":"publisher","first-page":"7837","DOI":"10.1073\/pnas.79.24.7837","volume":"79","author":"R Taub","year":"1982","unstructured":"Taub R, Kirsch I, Morton C, Lenoir G, Swan D, Tronick S, et al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci USA. 1982;79(24):7837\u201341. https:\/\/doi.org\/10.1073\/pnas.79.24.7837.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5931","key":"798_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/305245a0","volume":"305","author":"M Schwab","year":"1983","unstructured":"Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F, et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature. 1983;305(5931):245\u20138. https:\/\/doi.org\/10.1038\/305245a0.","journal-title":"Nature"},{"issue":"2 Pt 1","key":"798_CR7","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/0092-8674(83)90169-1","volume":"35","author":"NE Kohl","year":"1983","unstructured":"Kohl NE, Kanda N, Schreck RR, Bruns G, Latt SA, Gilbert F, et al. Transposition and amplification of oncogene-related sequences in human neuroblastomas. Cell. 1983;35(2 Pt 1):359\u201367. https:\/\/doi.org\/10.1016\/0092-8674(83)90169-1.","journal-title":"Cell"},{"issue":"6041","key":"798_CR8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/318069a0","volume":"318","author":"MM Nau","year":"1985","unstructured":"Nau MM, Brooks BJ, Battey J, Sausville E, Gazdar AF, Kirsch IR, et al. L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. Nature. 1985;318(6041):69\u201373. https:\/\/doi.org\/10.1038\/318069a0.","journal-title":"Nature"},{"key":"798_CR9","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a014217","author":"CV Dang","year":"2013","unstructured":"Dang CV. MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb Perspect Med. 2013. https:\/\/doi.org\/10.1101\/cshperspect.a014217.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"798_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41571-021-00549-2","volume":"19","author":"R Dhanasekaran","year":"2022","unstructured":"Dhanasekaran R, Deutzmann A, Mahauad-Fernandez WD, Hansen AS, Gouw AM, Felsher DW. The MYC oncogene\u2014the grand orchestrator of cancer growth and immune evasion. Nat Rev Clin Oncol. 2022;19(1):23\u201336. https:\/\/doi.org\/10.1038\/s41571-021-00549-2.","journal-title":"Nat Rev Clin Oncol"},{"key":"798_CR11","doi-asserted-by":"publisher","first-page":"1342872","DOI":"10.3389\/fcell.2024.1342872","volume":"12","author":"MF Zacar\u00edas-Fluck","year":"2024","unstructured":"Zacar\u00edas-Fluck MF, Soucek L, Whitfield JR. MYC: there is more to it than cancer. Front Cell Dev Biol. 2024;12:1342872. https:\/\/doi.org\/10.3389\/fcell.2024.1342872.","journal-title":"Front Cell Dev Biol."},{"issue":"3","key":"798_CR12","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3390\/pathophysiology30030027","volume":"30","author":"B Illi","year":"2023","unstructured":"Illi B, Nasi S. Myc beyond cancer: regulation of mammalian tissue regeneration. Pathophysiology. 2023;30(3):346\u201365. https:\/\/doi.org\/10.3390\/pathophysiology30030027.","journal-title":"Pathophysiology"},{"issue":"4998","key":"798_CR13","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1126\/science.2006410","volume":"251","author":"EM Blackwood","year":"1991","unstructured":"Blackwood EM, Eisenman RN. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science. 1991;251(4998):1211\u20137. https:\/\/doi.org\/10.1126\/science.2006410.","journal-title":"Science"},{"issue":"2","key":"798_CR14","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/s0959-437x(05)80278-3","volume":"2","author":"EM Blackwood","year":"1992","unstructured":"Blackwood EM, Kretzner L, Eisenman RN. Myc and Max function as a nucleoprotein complex. Curr Opin Genet Dev. 1992;2(2):227\u201335. https:\/\/doi.org\/10.1016\/s0959-437x(05)80278-3.","journal-title":"Curr Opin Genet Dev"},{"issue":"9","key":"798_CR15","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1093\/nar\/20.9.2257","volume":"20","author":"R Alex","year":"1992","unstructured":"Alex R, S\u00f6zeri O, Meyer S, Dildrop R. Determination of the DNA sequence recognized by the bHLH-zip domain of the N-Myc protein. Nucleic Acids Res. 1992;20(9):2257\u201363. https:\/\/doi.org\/10.1093\/nar\/20.9.2257.","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"798_CR16","first-page":"1093","volume":"8","author":"A Ma","year":"1993","unstructured":"Ma A, Moroy T, Collum R, Weintraub H, Alt FW, Blackwell TK. DNA binding by N- and L-Myc proteins. Oncogene. 1993;8(4):1093\u20138.","journal-title":"Oncogene"},{"issue":"13","key":"798_CR17","doi-asserted-by":"publisher","first-page":"5075","DOI":"10.1002\/j.1460-2075.1993.tb06201.x","volume":"12","author":"F Fisher","year":"1993","unstructured":"Fisher F, Crouch DH, Jayaraman PS, Clark W, Gillespie DA, Goding CR. Transcription activation by Myc and Max: flanking sequences target activation to a subset of CACGTG motifs in vivo. Embo J. 1993;12(13):5075\u201382. https:\/\/doi.org\/10.1002\/j.1460-2075.1993.tb06201.x.","journal-title":"Embo J"},{"issue":"4","key":"798_CR18","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41588-018-0044-9","volume":"50","author":"R Zeid","year":"2018","unstructured":"Zeid R, Lawlor MA, Poon E, Reyes JM, Fulciniti M, Lopez MA, et al. Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma. Nat Genet. 2018;50(4):515\u201323. https:\/\/doi.org\/10.1038\/s41588-018-0044-9.","journal-title":"Nat Genet"},{"issue":"1","key":"798_CR19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cell.2012.08.026","volume":"151","author":"CY Lin","year":"2012","unstructured":"Lin CY, Lov\u00e9n J, Rahl PB, Paranal RM, Burge CB, Bradner JE, et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell. 2012;151(1):56\u201367. https:\/\/doi.org\/10.1016\/j.cell.2012.08.026.","journal-title":"Cell"},{"issue":"1","key":"798_CR20","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.cell.2012.08.033","volume":"151","author":"Z Nie","year":"2012","unstructured":"Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W, et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell. 2012;151(1):68\u201379. https:\/\/doi.org\/10.1016\/j.cell.2012.08.033.","journal-title":"Cell"},{"issue":"7510","key":"798_CR21","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/nature13537","volume":"511","author":"A Sab\u00f2","year":"2014","unstructured":"Sab\u00f2 A, Kress TR, Pelizzola M, de Pretis S, Gorski MM, Tesi A, et al. Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis. Nature. 2014;511(7510):488\u201392. https:\/\/doi.org\/10.1038\/nature13537.","journal-title":"Nature"},{"issue":"9","key":"798_CR22","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201947987","volume":"20","author":"A Tesi","year":"2019","unstructured":"Tesi A, de Pretis S, Furlan M, Filipuzzi M, Morelli MJ, Andronache A, et al. An early Myc-dependent transcriptional program orchestrates cell growth during B-cell activation. EMBO Rep. 2019;20(9):EMBR201947987. https:\/\/doi.org\/10.15252\/embr.201947987.","journal-title":"EMBO Rep"},{"issue":"7510","key":"798_CR23","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nature13473","volume":"511","author":"S Walz","year":"2014","unstructured":"Walz S, Lorenzin F, Morton J, Wiese KE, von Eyss B, Herold S, et al. Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles. Nature. 2014;511(7510):483\u20137. https:\/\/doi.org\/10.1038\/nature13473.","journal-title":"Nature"},{"issue":"4","key":"798_CR24","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/35070076","volume":"3","author":"P Staller","year":"2001","unstructured":"Staller P, Peukert K, Kiermaier A, Seoane J, Lukas J, Karsunky H, et al. Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol. 2001;3(4):392\u20139. https:\/\/doi.org\/10.1038\/35070076.","journal-title":"Nat Cell Biol"},{"issue":"5","key":"798_CR25","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1002\/hep.26720","volume":"59","author":"L Wang","year":"2014","unstructured":"Wang L, Zhang X, Jia LT, Hu SJ, Zhao J, Yang JD, et al. c-Myc-mediated epigenetic silencing of microRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma. Hepatology. 2014;59(5):1850\u201363. https:\/\/doi.org\/10.1002\/hep.26720.","journal-title":"Hepatology"},{"key":"798_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/genes8050142","author":"CJ Poole","year":"2017","unstructured":"Poole CJ, van Riggelen J. MYC-master regulator of the cancer epigenome and transcriptome. Genes (Basel). 2017. https:\/\/doi.org\/10.3390\/genes8050142.","journal-title":"Genes (Basel)"},{"key":"798_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2013.00001","volume":"3","author":"S He","year":"2013","unstructured":"He S, Liu Z, Oh DY, Thiele CJ. MYCN and the epigenome. Front Oncol. 2013;3:1. https:\/\/doi.org\/10.3389\/fonc.2013.00001.","journal-title":"Front Oncol"},{"issue":"5","key":"798_CR28","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.molcel.2018.09.031","volume":"72","author":"M Kalkat","year":"2018","unstructured":"Kalkat M, Resetca D, Lourenco C, Chan PK, Wei Y, Shiah YJ, et al. MYC Protein interactome profiling reveals functionally distinct regions that cooperate to drive tumorigenesis. Mol Cell. 2018;72(5):836-48.e7. https:\/\/doi.org\/10.1016\/j.molcel.2018.09.031.","journal-title":"Mol Cell"},{"issue":"3","key":"798_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3002240","volume":"22","author":"Z Liu","year":"2024","unstructured":"Liu Z, Zhang X, Xu M, Hong JJ, Ciardiello A, Lei H, et al. MYCN drives oncogenesis by cooperating with the histone methyltransferase G9a and the WDR5 adaptor to orchestrate global gene transcription. PLoS Biol. 2024;22(3):e3002240. https:\/\/doi.org\/10.1371\/journal.pbio.3002240.","journal-title":"PLoS Biol"},{"issue":"Suppl 2","key":"798_CR30","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/s0169-5002(01)00343-9","volume":"34","author":"M Zajac-Kaye","year":"2001","unstructured":"Zajac-Kaye M. Myc oncogene: a key component in cell cycle regulation and its implication for lung cancer. Lung Cancer. 2001;34(Suppl 2):S43\u20136. https:\/\/doi.org\/10.1016\/s0169-5002(01)00343-9.","journal-title":"Lung Cancer"},{"issue":"18","key":"798_CR31","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1182\/blood-2017-11-742577","volume":"131","author":"SC Casey","year":"2018","unstructured":"Casey SC, Baylot V, Felsher DW. The MYC oncogene is a global regulator of the immune response. Blood. 2018;131(18):2007\u201315. https:\/\/doi.org\/10.1182\/blood-2017-11-742577.","journal-title":"Blood"},{"issue":"5","key":"798_CR32","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.bbagrm.2014.07.004","volume":"1849","author":"T Wahlstr\u00f6m","year":"2015","unstructured":"Wahlstr\u00f6m T, Arsenian Henriksson M. Impact of MYC in regulation of tumor cell metabolism. Biochim Biophys Acta (BBA) Gene Regul Mech. 2015;1849(5):563\u20139. https:\/\/doi.org\/10.1016\/j.bbagrm.2014.07.004.","journal-title":"Biochim Biophys Acta (BBA) Gene Regul Mech"},{"issue":"4","key":"798_CR33","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nrc2819","volume":"10","author":"J van Riggelen","year":"2010","unstructured":"van Riggelen J, Yetil A, Felsher DW. MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer. 2010;10(4):301\u20139. https:\/\/doi.org\/10.1038\/nrc2819.","journal-title":"Nat Rev Cancer"},{"key":"798_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24098141","author":"P Agarwal","year":"2023","unstructured":"Agarwal P, Glowacka A, Mahmoud L, Bazzar W, Larsson LG, Alzrigat M. MYCN amplification is associated with reduced expression of genes encoding \u03b3-secretase complex and NOTCH signaling components in neuroblastoma. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24098141.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"798_CR35","doi-asserted-by":"publisher","first-page":"a014381","DOI":"10.1101\/cshperspect.a014381","volume":"3","author":"J Chappell","year":"2013","unstructured":"Chappell J, Dalton S. Roles for MYC in the establishment and maintenance of pluripotency. Cold Spring Harb Perspect Med. 2013;3(12):a014381. https:\/\/doi.org\/10.1101\/cshperspect.a014381.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"7213","key":"798_CR36","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/nature07260","volume":"455","author":"L Soucek","year":"2008","unstructured":"Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, et al. Modelling Myc inhibition as a cancer therapy. Nature. 2008;455(7213):679\u201383. https:\/\/doi.org\/10.1038\/nature07260.","journal-title":"Nature"},{"issue":"3","key":"798_CR37","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41591-024-02805-1","volume":"30","author":"E Garralda","year":"2024","unstructured":"Garralda E, Beaulieu ME, Moreno V, Casacuberta-Serra S, Mart\u00ednez-Mart\u00edn S, Foradada L, et al. MYC targeting by OMO-103 in solid tumors: a phase 1 trial. Nat Med. 2024;30(3):762\u201371. https:\/\/doi.org\/10.1038\/s41591-024-02805-1.","journal-title":"Nat Med"},{"issue":"10","key":"798_CR38","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41573-025-01220-6","volume":"24","author":"T Lazar","year":"2025","unstructured":"Lazar T, Connor A, DeLisle CF, Burger V, Tompa P. Targeting protein disorder: the next hurdle in drug discovery. Nat Rev Drug Discov. 2025;24(10):743\u201363. https:\/\/doi.org\/10.1038\/s41573-025-01220-6.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"798_CR39","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/nar\/gkac138","volume":"50","author":"Y Wei","year":"2022","unstructured":"Wei Y, Redel C, Ahlner A, Lemak A, Johansson-\u00c5khe I, Houliston S, et al. The MYC oncoprotein directly interacts with its chromatin cofactor PNUTS to recruit PP1 phosphatase. Nucleic Acids Res. 2022;50(6):3505\u201322. https:\/\/doi.org\/10.1093\/nar\/gkac138.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"798_CR40","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jmb.2005.05.046","volume":"351","author":"A Pineda-Lucena","year":"2005","unstructured":"Pineda-Lucena A, Ho CS, Mao DY, Sheng Y, Laister RC, Muhandiram R, et al. A structure-based model of the c-Myc\/Bin1 protein interaction shows alternative splicing of Bin1 and c-Myc phosphorylation are key binding determinants. J Mol Biol. 2005;351(1):182\u201394. https:\/\/doi.org\/10.1016\/j.jmb.2005.05.046.","journal-title":"J Mol Biol"},{"issue":"11","key":"798_CR41","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/s41594-019-0321-z","volume":"26","author":"Y Wei","year":"2019","unstructured":"Wei Y, Resetca D, Li Z, Johansson-\u00c5khe I, Ahlner A, Helander S, et al. Multiple direct interactions of TBP with the MYC oncoprotein. Nat Struct Mol Biol. 2019;26(11):1035\u201343. https:\/\/doi.org\/10.1038\/s41594-019-0321-z.","journal-title":"Nat Struct Mol Biol"},{"key":"798_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-69725-1","author":"J Hultman","year":"2026","unstructured":"Hultman J, Morad V, Tanner E, Kenney TMG, Pietras Z, Khare LP, et al. The N-Myc MB0-MBI region interacts specifically and dynamically with the N-lobe of Aurora kinase A. Nat Commun. 2026. https:\/\/doi.org\/10.1038\/s41467-026-69725-1.","journal-title":"Nat Commun"},{"issue":"48","key":"798_CR43","doi-asserted-by":"publisher","first-page":"13726","DOI":"10.1073\/pnas.1610626113","volume":"113","author":"MW Richards","year":"2016","unstructured":"Richards MW, Burgess SG, Poon E, Carstensen A, Eilers M, Chesler L, et al. Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors. Proc Natl Acad Sci USA. 2016;113(48):13726\u201331. https:\/\/doi.org\/10.1073\/pnas.1610626113.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"798_CR44","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.molcel.2015.02.028","volume":"58","author":"LR Thomas","year":"2015","unstructured":"Thomas LR, Wang Q, Grieb BC, Phan J, Foshage AM, Sun Q, et al. Interaction with WDR5 promotes target gene recognition and tumorigenesis by MYC. Mol Cell. 2015;58(3):440\u201352. https:\/\/doi.org\/10.1016\/j.molcel.2015.02.028.","journal-title":"Mol Cell"},{"issue":"9","key":"798_CR45","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1007\/s00018-019-03347-3","volume":"77","author":"P Santofimia-Casta\u00f1o","year":"2020","unstructured":"Santofimia-Casta\u00f1o P, Rizzuti B, Xia Y, Abian O, Peng L, Vel\u00e1zquez-Campoy A, et al. Targeting intrinsically disordered proteins involved in cancer. Cell Mol Life Sci. 2020;77(9):1695\u2013707. https:\/\/doi.org\/10.1007\/s00018-019-03347-3.","journal-title":"Cell Mol Life Sci"},{"issue":"4705","key":"798_CR46","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1126\/science.4001943","volume":"228","author":"L Kaczmarek","year":"1985","unstructured":"Kaczmarek L, Hyland JK, Watt R, Rosenberg M, Baserga R. Microinjected c-myc as a competence factor. Science. 1985;228(4705):1313\u20135. https:\/\/doi.org\/10.1126\/science.4001943.","journal-title":"Science"},{"issue":"19","key":"798_CR47","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.1002\/j.1460-2075.1995.tb00163.x","volume":"14","author":"P Steiner","year":"1995","unstructured":"Steiner P, Philipp A, Lukas J, Godden-Kent D, Pagano M, Mittnacht S, et al. Identification of a Myc-dependent step during the formation of active G1 cyclin-cdk complexes. Embo J. 1995;14(19):4814\u201326. https:\/\/doi.org\/10.1002\/j.1460-2075.1995.tb00163.x.","journal-title":"Embo J"},{"issue":"4","key":"798_CR48","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","volume":"126","author":"K Takahashi","year":"2006","unstructured":"Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663\u201376. https:\/\/doi.org\/10.1016\/j.cell.2006.07.024.","journal-title":"Cell"},{"issue":"7151","key":"798_CR49","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nature05934","volume":"448","author":"K Okita","year":"2007","unstructured":"Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature. 2007;448(7151):313\u20137. https:\/\/doi.org\/10.1038\/nature05934.","journal-title":"Nature"},{"issue":"1","key":"798_CR50","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/joim.12237","volume":"276","author":"Y Li","year":"2014","unstructured":"Li Y, Casey SC, Felsher DW. Inactivation of MYC reverses tumorigenesis. J Intern Med. 2014;276(1):52\u201360. https:\/\/doi.org\/10.1111\/joim.12237.","journal-title":"J Intern Med"},{"issue":"6","key":"798_CR51","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.cell.2017.11.013","volume":"171","author":"RM Kortlever","year":"2017","unstructured":"Kortlever RM, Sodir NM, Wilson CH, Burkhart DL, Pellegrinet L, Brown Swigart L, et al. Myc cooperates with Ras by programming inflammation and immune suppression. Cell. 2017;171(6):1301-15.e14. https:\/\/doi.org\/10.1016\/j.cell.2017.11.013.","journal-title":"Cell"},{"issue":"2","key":"798_CR52","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/s1097-2765(00)80367-6","volume":"4","author":"DW Felsher","year":"1999","unstructured":"Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell. 1999;4(2):199\u2013207. https:\/\/doi.org\/10.1016\/s1097-2765(00)80367-6.","journal-title":"Mol Cell"},{"issue":"10","key":"798_CR53","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1158\/2159-8290.Cd-15-0507","volume":"5","author":"ZE Stine","year":"2015","unstructured":"Stine ZE, Walton ZE, Altman BJ, Hsieh AL, Dang CV. MYC, metabolism, and cancer. Cancer Discov. 2015;5(10):1024\u201339. https:\/\/doi.org\/10.1158\/2159-8290.Cd-15-0507.","journal-title":"Cancer Discov"},{"issue":"9","key":"798_CR54","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.4161\/cc.6.9.4161","volume":"6","author":"EV Prochownik","year":"2007","unstructured":"Prochownik EV, Li Y. The ever expanding role for c-Myc in promoting genomic instability. Cell Cycle. 2007;6(9):1024\u20139. https:\/\/doi.org\/10.4161\/cc.6.9.4161.","journal-title":"Cell Cycle"},{"issue":"17","key":"798_CR55","doi-asserted-by":"publisher","first-page":"9974","DOI":"10.1073\/pnas.1732638100","volume":"100","author":"A Karlsson","year":"2003","unstructured":"Karlsson A, Deb-Basu D, Cherry A, Turner S, Ford J, Felsher DW. Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression. Proc Natl Acad Sci. 2003;100(17):9974\u20139. https:\/\/doi.org\/10.1073\/pnas.1732638100.","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"798_CR56","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/s1097-2765(02)00520-8","volume":"9","author":"O Vafa","year":"2002","unstructured":"Vafa O, Wade M, Kern S, Beeche M, Pandita TK, Hampton GM, et al. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell. 2002;9(5):1031\u201344. https:\/\/doi.org\/10.1016\/s1097-2765(02)00520-8.","journal-title":"Mol Cell"},{"issue":"11","key":"798_CR57","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/nrc2728","volume":"9","author":"MR Junttila","year":"2009","unstructured":"Junttila MR, Evan GI. P53 \u2014 a jack of all trades but master of none. Nat Rev Cancer. 2009;9(11):821\u20139. https:\/\/doi.org\/10.1038\/nrc2728.","journal-title":"Nat Rev Cancer"},{"issue":"7015","key":"798_CR58","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nature03098","volume":"432","author":"SW Lowe","year":"2004","unstructured":"Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature. 2004;432(7015):307\u201315. https:\/\/doi.org\/10.1038\/nature03098.","journal-title":"Nature"},{"issue":"15","key":"798_CR59","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1101\/gad.12.15.2424","volume":"12","author":"F Zindy","year":"1998","unstructured":"Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 1998;12(15):2424\u201333. https:\/\/doi.org\/10.1101\/gad.12.15.2424.","journal-title":"Genes Dev"},{"issue":"11","key":"798_CR60","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/j.molcel.2024.04.007","volume":"84","author":"D Papadopoulos","year":"2024","unstructured":"Papadopoulos D, Ha SA, Fleischhauer D, Uhl L, Russell TJ, Mikicic I, et al. The MYCN oncoprotein is an RNA-binding accessory factor of the nuclear exosome targeting complex. Mol Cell. 2024;84(11):2070-86.e20. https:\/\/doi.org\/10.1016\/j.molcel.2024.04.007.","journal-title":"Mol Cell"},{"issue":"7938","key":"798_CR61","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41586-022-05469-4","volume":"612","author":"D Solvie","year":"2022","unstructured":"Solvie D, Baluapuri A, Uhl L, Fleischhauer D, Endres T, Papadopoulos D, et al. MYC multimers shield stalled replication forks from RNA polymerase. Nature. 2022;612(7938):148\u201355. https:\/\/doi.org\/10.1038\/s41586-022-05469-4.","journal-title":"Nature"},{"issue":"32","key":"798_CR62","doi-asserted-by":"publisher","first-page":"13028","DOI":"10.1073\/pnas.0701953104","volume":"104","author":"C-H Wu","year":"2007","unstructured":"Wu C-H, van Riggelen J, Yetil A, Fan AC, Bachireddy P, Felsher DW. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci. 2007;104(32):13028\u201333. https:\/\/doi.org\/10.1073\/pnas.0701953104.","journal-title":"Proc Natl Acad Sci"},{"issue":"13","key":"798_CR63","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1101\/gad.1100303","volume":"17","author":"C Grandori","year":"2003","unstructured":"Grandori C, Wu KJ, Fernandez P, Ngouenet C, Grim J, Clurman BE, et al. Werner syndrome protein limits MYC-induced cellular senescence. Genes Dev. 2003;17(13):1569\u201374. https:\/\/doi.org\/10.1101\/gad.1100303.","journal-title":"Genes Dev"},{"issue":"24","key":"798_CR64","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1080\/15384101.2018.1553339","volume":"17","author":"F Zhang","year":"2018","unstructured":"Zhang F, Zakaria SM, H\u00f6gqvist Tabor V, Singh M, Tronnersj\u00f6 S, Goodwin J, et al. MYC and RAS are unable to cooperate in overcoming cellular senescence and apoptosis in normal human fibroblasts. Cell Cycle. 2018;17(24):2697\u2013715. https:\/\/doi.org\/10.1080\/15384101.2018.1553339.","journal-title":"Cell Cycle"},{"issue":"18","key":"798_CR65","doi-asserted-by":"publisher","first-page":"6563","DOI":"10.1158\/0008-5472.Can-03-3176","volume":"64","author":"UE Knies-Bamforth","year":"2004","unstructured":"Knies-Bamforth UE, Fox SB, Poulsom R, Evan GI, Harris AL. C-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism. Cancer Res. 2004;64(18):6563\u201370. https:\/\/doi.org\/10.1158\/0008-5472.Can-03-3176.","journal-title":"Cancer Res"},{"issue":"2","key":"798_CR66","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1080\/21541248.2017.1364821","volume":"11","author":"N Venkateswaran","year":"2020","unstructured":"Venkateswaran N, Conacci-Sorrell M. MYC leads the way. Small GTPases. 2020;11(2):86\u201394. https:\/\/doi.org\/10.1080\/21541248.2017.1364821.","journal-title":"Small GTPases"},{"issue":"3","key":"798_CR67","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1158\/2159-8290.Cd-13-0346","volume":"4","author":"H Cho","year":"2014","unstructured":"Cho H, Herzka T, Zheng W, Qi J, Wilkinson JE, Bradner JE, et al. RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis. Cancer Discov. 2014;4(3):318\u201333. https:\/\/doi.org\/10.1158\/2159-8290.Cd-13-0346.","journal-title":"Cancer Discov"},{"issue":"6","key":"798_CR68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006029","volume":"4","author":"UR Rapp","year":"2009","unstructured":"Rapp UR, Korn C, Ceteci F, Karreman C, Luetkenhaus K, Serafin V, et al. MYC is a metastasis gene for non-small-cell lung cancer. PLoS\u00a0One. 2009;4(6):e6029. https:\/\/doi.org\/10.1371\/journal.pone.0006029.","journal-title":"PLoS\u00a0One"},{"issue":"5","key":"798_CR69","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.cell.2025.12.019","volume":"189","author":"L Uhl","year":"2026","unstructured":"Uhl L, Aziba A, L\u00f6bbert S, Russell T, Krenz B, Montesinos F, et al. MYC binding to nascent RNA suppresses innate immune signaling by R-loop-derived RNA-DNA hybrids. Cell. 2026;189(5):1371-88.e29. https:\/\/doi.org\/10.1016\/j.cell.2025.12.019.","journal-title":"Cell"},{"issue":"16","key":"798_CR70","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1158\/0008-5472.Can-21-1677","volume":"81","author":"B Krenz","year":"2021","unstructured":"Krenz B, Gebhardt-Wolf A, Ade CP, Gaballa A, Roehrig F, Vendelova E, et al. MYC- and MIZ1-dependent vesicular transport of double-strand RNA controls immune evasion in pancreatic ductal adenocarcinoma. Cancer Res. 2021;81(16):4242\u201356. https:\/\/doi.org\/10.1158\/0008-5472.Can-21-1677.","journal-title":"Cancer Res"},{"issue":"6282","key":"798_CR71","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1126\/science.aac9935","volume":"352","author":"SC Casey","year":"2016","unstructured":"Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016;352(6282):227\u201331. https:\/\/doi.org\/10.1126\/science.aac9935.","journal-title":"Science"},{"issue":"4","key":"798_CR72","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/j.1460-2075.1988.tb02909.x","volume":"7","author":"R Versteeg","year":"1988","unstructured":"Versteeg R, Noordermeer IA, Kr\u00fcse\u2010Wolters M, Ruiter DJ, Schrier PI. c\u2010myc down\u2010regulates class I HLA expression in human melanomas. EMBO J. 1988;7(4):1023\u20139. https:\/\/doi.org\/10.1002\/j.1460-2075.1988.tb02909.x.","journal-title":"EMBO J"},{"issue":"6","key":"798_CR73","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1038\/oncsis.2014.20","volume":"3","author":"R Lu","year":"2014","unstructured":"Lu R, Wu S, Zhang YG, Xia Y, Liu X, Zheng Y, et al. Enteric bacterial protein AvrA promotes colonic tumorigenesis and activates colonic beta-catenin signaling pathway. Oncogenesis. 2014;3(6):e105. https:\/\/doi.org\/10.1038\/oncsis.2014.20.","journal-title":"Oncogenesis"},{"issue":"1","key":"798_CR74","doi-asserted-by":"publisher","first-page":"2186114","DOI":"10.1080\/19490976.2023.2186114","volume":"15","author":"H Xu","year":"2023","unstructured":"Xu H, Luo H, Zhang J, Li K, Lee M-H. Therapeutic potential of Clostridium butyricum anticancer effects in colorectal cancer. Gut Microbes. 2023;15(1):2186114. https:\/\/doi.org\/10.1080\/19490976.2023.2186114.","journal-title":"Gut Microbes"},{"issue":"10","key":"798_CR75","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/nrc3984","volume":"15","author":"TR Kress","year":"2015","unstructured":"Kress TR, Sab\u00f2 A, Amati B. MYC: connecting selective transcriptional control to global RNA production. Nat Rev Cancer. 2015;15(10):593\u2013607. https:\/\/doi.org\/10.1038\/nrc3984.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"798_CR76","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/nrc2231","volume":"8","author":"N Meyer","year":"2008","unstructured":"Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008;8(12):976\u201390. https:\/\/doi.org\/10.1038\/nrc2231.","journal-title":"Nat Rev Cancer"},{"key":"798_CR77","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1146\/annurev-cancerbio-030518-055826","volume":"4","author":"E Wolf","year":"2020","unstructured":"Wolf E, Eilers M. Targeting MYC proteins for tumor therapy. Ann Revi Cancer Biol. 2020;4:61\u201375. https:\/\/doi.org\/10.1146\/annurev-cancerbio-030518-055826.","journal-title":"Ann Revi Cancer Biol."},{"issue":"17-18","key":"798_CR78","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1101\/gad.325878.119","volume":"33","author":"H Mathsyaraja","year":"2019","unstructured":"Mathsyaraja H, Freie B, Cheng PF, Babaeva E, Catchpole JT, Janssens D, et al. Max deletion destabilizes MYC protein and abrogates E\u00b5-Myc lymphomagenesis. Genes Dev. 2019;33(17\u201318):1252\u201364. https:\/\/doi.org\/10.1101\/gad.325878.119.","journal-title":"Genes Dev"},{"issue":"6","key":"798_CR79","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s41573-025-01143-2","volume":"24","author":"JR Whitfield","year":"2025","unstructured":"Whitfield JR, Soucek L. MYC in cancer: from undruggable target to clinical trials. Nat Rev Drug Discov. 2025;24(6):445\u201357. https:\/\/doi.org\/10.1038\/s41573-025-01143-2.","journal-title":"Nat Rev Drug Discov"},{"key":"798_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103756","volume":"75","author":"V Llombart","year":"2022","unstructured":"Llombart V, Mansour MR. Therapeutic targeting of \u201cundruggable\u201d MYC. EBioMedicine. 2022;75:103756. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103756.","journal-title":"EBioMedicine"},{"issue":"5","key":"798_CR81","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s40259-019-00370-5","volume":"33","author":"BL Allen-Petersen","year":"2019","unstructured":"Allen-Petersen BL, Sears RC. Mission possible: advances in MYC therapeutic targeting in cancer. BioDrugs. 2019;33(5):539\u201353. https:\/\/doi.org\/10.1007\/s40259-019-00370-5.","journal-title":"BioDrugs"},{"issue":"40","key":"798_CR82","doi-asserted-by":"publisher","first-page":"6151","DOI":"10.1038\/sj.onc.1206641","volume":"22","author":"X Yin","year":"2003","unstructured":"Yin X, Giap C, Lazo JS, Prochownik EV. Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene. 2003;22(40):6151\u20139. https:\/\/doi.org\/10.1038\/sj.onc.1206641.","journal-title":"Oncogene"},{"issue":"6","key":"798_CR83","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1073\/pnas.062036999","volume":"99","author":"T Berg","year":"2002","unstructured":"Berg T, Cohen SB, Desharnais J, Sonderegger C, Maslyar DJ, Goldberg J, et al. Small-molecule antagonists of Myc\/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc Natl Acad Sci USA. 2002;99(6):3830\u20135. https:\/\/doi.org\/10.1073\/pnas.062036999.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"798_CR84","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ccell.2019.10.001","volume":"36","author":"H Han","year":"2019","unstructured":"Han H, Jain AD, Truica MI, Izquierdo-Ferrer J, Anker JF, Lysy B, et al. Small-molecule MYC inhibitors suppress tumor growth and enhance immunotherapy. Cancer Cell. 2019;36(5):483-97.e15. https:\/\/doi.org\/10.1016\/j.ccell.2019.10.001.","journal-title":"Cancer Cell"},{"issue":"17","key":"798_CR85","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abh3635","volume":"8","author":"AG Holmes","year":"2022","unstructured":"Holmes AG, Parker JB, Sagar V, Truica MI, Soni PN, Han H, et al. A MYC inhibitor selectively alters the MYC and MAX cistromes and modulates the epigenomic landscape to regulate target gene expression. Sci Adv. 2022;8(17):eabh3635. https:\/\/doi.org\/10.1126\/sciadv.abh3635.","journal-title":"Sci Adv"},{"issue":"14","key":"798_CR86","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1158\/1078-0432.Ccr-24-0256","volume":"30","author":"LN Davis","year":"2024","unstructured":"Davis LN, Walker ZJ, Reiman LT, Parzych SE, Stevens BM, Jordan CT, et al. MYC inhibition potentiates CD8+ T cells against multiple myeloma and overcomes immunomodulatory drug resistance. Clin Cancer Res. 2024;30(14):3023\u201335. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-0256.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"798_CR87","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1038\/sj.onc.1202199","volume":"17","author":"L Soucek","year":"1998","unstructured":"Soucek L, Helmer-Citterich M, Sacco A, Jucker R, Cesareni G, Nasi S. Design and properties of a Myc derivative that efficiently homodimerizes. Oncogene. 1998;17(19):2463\u201372. https:\/\/doi.org\/10.1038\/sj.onc.1202199.","journal-title":"Oncogene"},{"key":"798_CR88","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.00248-19","author":"MJ Demma","year":"2019","unstructured":"Demma MJ, Mapelli C, Sun A, Bodea S, Ruprecht B, Javaid S, et al. Omomyc reveals new mechanisms to inhibit the MYC oncogene. Mol Cell Biol. 2019. https:\/\/doi.org\/10.1128\/mcb.00248-19.","journal-title":"Mol Cell Biol"},{"issue":"2","key":"798_CR89","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1158\/2767-9764.Crc-21-0103","volume":"2","author":"D Mass\u00f3-Vall\u00e9s","year":"2022","unstructured":"Mass\u00f3-Vall\u00e9s D, Beaulieu M-E, Jauset T, Giuntini F, Zacar\u00edas-Fluck MF, Foradada L, et al. MYC inhibition halts metastatic breast cancer progression by blocking growth, invasion, and seeding. Cancer Res Comm. 2022;2(2):110\u201330. https:\/\/doi.org\/10.1158\/2767-9764.Crc-21-0103.","journal-title":"Cancer Res Comm."},{"key":"798_CR90","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aar5012","author":"ME Beaulieu","year":"2019","unstructured":"Beaulieu ME, Jauset T, Mass\u00f3-Vall\u00e9s D, Mart\u00ednez-Mart\u00edn S, Rahl P, Maltais L, et al. Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy. Sci Transl Med. 2019. https:\/\/doi.org\/10.1126\/scitranslmed.aar5012.","journal-title":"Sci Transl Med"},{"issue":"7","key":"798_CR91","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2310479121","volume":"121","author":"L Sainero-Alcolado","year":"2024","unstructured":"Sainero-Alcolado L, Garde-Lapido E, Snaebj\u00f6rnsson MT, Schoch S, Stevens I, Ruiz-P\u00e9rez MV, et al. Targeting MYC induces lipid droplet accumulation by upregulation of HILPDA in clear cell renal cell carcinoma. Proc Natl Acad Sci USA. 2024;121(7):e2310479121. https:\/\/doi.org\/10.1073\/pnas.2310479121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"798_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.chempr.2025.102839","author":"JP Kahler","year":"2025","unstructured":"Kahler JP, Ellenbroek BD, van der Noord VE, van de Water B, Pomplun SJ. ReCHEMbinant stapling enhances intracellular delivery and bioactivity of engineered protein inhibitors. Chemistry (Weinheim an der Bergstrasse, Germany). 2025. https:\/\/doi.org\/10.1016\/j.chempr.2025.102839.","journal-title":"Chemistry (Weinheim an der Bergstrasse, Germany)"},{"issue":"4","key":"798_CR93","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202416082","volume":"64","author":"BD Ellenbroek","year":"2025","unstructured":"Ellenbroek BD, Kahler JP, Arella D, Lin C, Jespers W, Z\u00fcger EA, et al. Development of DuoMYC: a synthetic cell penetrant miniprotein that efficiently inhibits the oncogenic transcription factor MYC. Angew Chem Int Ed Engl. 2025;64(4):e202416082. https:\/\/doi.org\/10.1002\/anie.202416082.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"22","key":"798_CR94","doi-asserted-by":"publisher","first-page":"7839","DOI":"10.1021\/ja901306q","volume":"131","author":"J Xu","year":"2009","unstructured":"Xu J, Chen G, De Jong AT, Shahravan SH, Shin JA. Max-E47, a designed minimalist protein that targets the E-box DNA site in vivo and in vitro. J Am Chem Soc. 2009;131(22):7839\u201348. https:\/\/doi.org\/10.1021\/ja901306q.","journal-title":"J Am Chem Soc"},{"issue":"2","key":"798_CR95","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032136","volume":"7","author":"F Ahmadpour","year":"2012","unstructured":"Ahmadpour F, Ghirlando R, De Jong AT, Gloyd M, Shin JA, Guarn\u00e9 A. Crystal structure of the minimalist Max-E47 protein chimera. PLoS\u00a0One. 2012;7(2):e32136. https:\/\/doi.org\/10.1371\/journal.pone.0032136.","journal-title":"PLoS\u00a0One"},{"issue":"49","key":"798_CR96","doi-asserted-by":"publisher","first-page":"6830","DOI":"10.1038\/onc.2017.275","volume":"36","author":"LC Lustig","year":"2017","unstructured":"Lustig LC, Dingar D, Tu WB, Lourenco C, Kalkat M, Inamoto I, et al. Inhibiting MYC binding to the E-box DNA motif by ME47 decreases tumour xenograft growth. Oncogene. 2017;36(49):6830\u20137. https:\/\/doi.org\/10.1038\/onc.2017.275.","journal-title":"Oncogene"},{"issue":"1","key":"798_CR97","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1021\/acschembio.0c00684","volume":"16","author":"I Inamoto","year":"2021","unstructured":"Inamoto I, Sheoran I, Popa SC, Hussain M, Shin JA. Combining rational design and continuous evolution on minimalist proteins that target the E-box DNA site. ACS Chem Biol. 2021;16(1):35\u201344. https:\/\/doi.org\/10.1021\/acschembio.0c00684.","journal-title":"ACS Chem Biol"},{"issue":"24","key":"798_CR98","doi-asserted-by":"publisher","first-page":"8989","DOI":"10.1073\/pnas.0509880103","volume":"103","author":"JM Mason","year":"2006","unstructured":"Mason JM, Schmitz MA, M\u00fcller KM, Arndt KM. Semirational design of Jun-Fos coiled coils with increased affinity: universal implications for leucine zipper prediction and design. Proc Natl Acad Sci USA. 2006;103(24):8989\u201394. https:\/\/doi.org\/10.1073\/pnas.0509880103.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"18","key":"798_CR99","doi-asserted-by":"publisher","first-page":"19331","DOI":"10.1021\/acs.jmedchem.5c01493","volume":"68","author":"M Ali","year":"2025","unstructured":"Ali M, Akel R, He F, Piquette-Miller M, Shin JA. Designer Frankenproteins that halt the proliferation of Myc-driven cancer cells. J Med Chem. 2025;68(18):19331\u20138. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c01493.","journal-title":"J Med Chem"},{"issue":"4","key":"798_CR100","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41587-022-01504-x","volume":"41","author":"TE Speltz","year":"2023","unstructured":"Speltz TE, Qiao Z, Swenson CS, Shangguan X, Coukos JS, Lee CW, et al. Targeting MYC with modular synthetic transcriptional repressors derived from bHLH DNA-binding domains. Nat Biotechnol. 2023;41(4):541\u201351. https:\/\/doi.org\/10.1038\/s41587-022-01504-x.","journal-title":"Nat Biotechnol"},{"issue":"10","key":"798_CR101","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1002\/1873-3468.13759","volume":"594","author":"MJ Demma","year":"2020","unstructured":"Demma MJ, Hohn MJ, Sun A, Mapelli C, Hall B, Walji A, et al. Inhibition of Myc transcriptional activity by a mini-protein based upon Mxd1. FEBS Lett. 2020;594(10):1467\u201376. https:\/\/doi.org\/10.1002\/1873-3468.13759.","journal-title":"FEBS Lett"},{"issue":"18","key":"798_CR102","doi-asserted-by":"publisher","first-page":"6584","DOI":"10.1073\/pnas.0802785105","volume":"105","author":"J Zhu","year":"2008","unstructured":"Zhu J, Blenis J, Yuan J. Activation of PI3K\/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. Proc Natl Acad Sci USA. 2008;105(18):6584\u20139. https:\/\/doi.org\/10.1073\/pnas.0802785105.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"13_Supplement","key":"798_CR103","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1158\/1538-7445.Am2021-2471","volume":"81","author":"C Calvis","year":"2021","unstructured":"Calvis C, Beier A, Feichtinger M, H\u00f6furthner T, Moreno M, Messeguer R, et al. Abstract 2471: IDP-121, a first in class staple peptide targeting c-MYC. Cancer Res. 2021;81(13_Supplement):2471. https:\/\/doi.org\/10.1158\/1538-7445.Am2021-2471.","journal-title":"Cancer Res"},{"issue":"8","key":"798_CR104","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1039\/c8sc03759k","volume":"10","author":"D Lama","year":"2019","unstructured":"Lama D, Liberatore AM, Frosi Y, Nakhle J, Tsomaia N, Bashir T, et al. Structural insights reveal a recognition feature for tailoring hydrocarbon stapled-peptides against the eukaryotic translation initiation factor 4E protein. Chem Sci. 2019;10(8):2489\u2013500. https:\/\/doi.org\/10.1039\/c8sc03759k.","journal-title":"Chem Sci"},{"key":"798_CR105","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1038\/srep03451","volume":"3","author":"D Lama","year":"2013","unstructured":"Lama D, Quah ST, Verma CS, Lakshminarayanan R, Beuerman RW, Lane DP, et al. Rational optimization of conformational effects induced by hydrocarbon staples in peptides and their binding interfaces. Sci Rep. 2013;3:3451. https:\/\/doi.org\/10.1038\/srep03451.","journal-title":"Sci Rep"},{"issue":"23","key":"798_CR106","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202500740","volume":"20","author":"BD Ellenbroek","year":"2025","unstructured":"Ellenbroek BD, Tirtosentono ASS, Pomplun SJ. AlphaFold-guided discovery of an overlapping MYC\/Miz-1 interface enables peptidomimetic disruption of MYC\/MAX. ChemMedChem. 2025;20(23):e202500740. https:\/\/doi.org\/10.1002\/cmdc.202500740.","journal-title":"ChemMedChem"},{"issue":"52","key":"798_CR107","doi-asserted-by":"publisher","first-page":"12690","DOI":"10.1002\/chem.201702117","volume":"23","author":"CA Rhodes","year":"2017","unstructured":"Rhodes CA, Pei D. Bicyclic peptides as next-generation therapeutics. Chemistry. 2017;23(52):12690\u2013703. https:\/\/doi.org\/10.1002\/chem.201702117.","journal-title":"Chemistry"},{"issue":"2","key":"798_CR108","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1021\/jacs.3c09615","volume":"146","author":"Z Li","year":"2024","unstructured":"Li Z, Huang Y, Hung TI, Sun J, Aispuro D, Chen B, et al. MYC-targeting inhibitors generated from a stereodiversified bicyclic peptide library. J Am Chem Soc. 2024;146(2):1356\u201363. https:\/\/doi.org\/10.1021\/jacs.3c09615.","journal-title":"J Am Chem Soc"},{"issue":"16","key":"798_CR109","first-page":"3654","volume":"58","author":"L Giorello","year":"1998","unstructured":"Giorello L, Clerico L, Pescarolo MP, Vikhanskaya F, Salmona M, Colella G, et al. Inhibition of cancer cell growth and c-Myc transcriptional activity by a c-Myc helix 1-type peptide fused to an internalization sequence. Cancer Res. 1998;58(16):3654\u20139.","journal-title":"Cancer Res"},{"issue":"1","key":"798_CR110","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1038\/s41467-024-45826-7","volume":"15","author":"D Lama","year":"2024","unstructured":"Lama D, Vosselman T, Sahin C, Lia\u00f1o-Pons J, Cerrato CP, Nilsson L, et al. A druggable conformational switch in the c-MYC transactivation domain. Nat Commun. 2024;15(1):1865. https:\/\/doi.org\/10.1038\/s41467-024-45826-7.","journal-title":"Nat Commun"},{"issue":"5","key":"798_CR111","doi-asserted-by":"publisher","first-page":"pgaf152","DOI":"10.1093\/pnasnexus\/pgaf152","volume":"4","author":"T Vosselman","year":"2025","unstructured":"Vosselman T, Sahin C, Lane DP, Arsenian Henriksson M, Landreh M, Lama D. Conformational modulation of intrinsically disordered transactivation domains for cancer therapy. PNAS Nexus. 2025;4(5):pgaf152. https:\/\/doi.org\/10.1093\/pnasnexus\/pgaf152.","journal-title":"PNAS Nexus."},{"issue":"3, Supplement 1","key":"798_CR112","doi-asserted-by":"publisher","first-page":"14a","DOI":"10.1016\/j.bpj.2024.11.147","volume":"124","author":"T Vosselman","year":"2025","unstructured":"Vosselman T, Sahin C, Teilum K, Lane DP, Arsenian-Henriksson M, Landreh M, et al. BPS2025 - modulation of c-MYC structure and activity by targeting a conformational switch. Biophys J. 2025;124(3, Supplement 1):14a-a15. https:\/\/doi.org\/10.1016\/j.bpj.2024.11.147.","journal-title":"Biophys J"},{"issue":"3","key":"798_CR113","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M B\u00e9k\u00e9s","year":"2022","unstructured":"B\u00e9k\u00e9s M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022;21(3):181\u2013200. https:\/\/doi.org\/10.1038\/s41573-021-00371-6.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"798_CR114","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1021\/acschembio.4c00864","volume":"20","author":"SR Boyd","year":"2025","unstructured":"Boyd SR, Chamakuri S, Trostle AJ, Chen H, Liu Z, Jian A, et al. MYC-targeting PROTACs lead to bimodal degradation and N-terminal truncation. ACS Chem Biol. 2025;20(4):896\u2013906. https:\/\/doi.org\/10.1021\/acschembio.4c00864.","journal-title":"ACS Chem Biol"},{"issue":"12","key":"798_CR115","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.1021\/acsptsci.4c00452","volume":"7","author":"C Siokatas","year":"2024","unstructured":"Siokatas C, Lampropoulou A, Smina A, Soupsana K, Kontostathi M, Karra AV, et al. Developing MYC degraders bearing the Von Hippel-Lindau ligand to target the \u201cundruggable\u201d MYC. ACS Pharmacol Transl Sci. 2024;7(12):3955\u201368. https:\/\/doi.org\/10.1021\/acsptsci.4c00452.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"798_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116978","volume":"280","author":"M Ai","year":"2024","unstructured":"Ai M, Ma H, He J, Xu F, Ming Y, Ye Z, et al. Targeting oncogenic transcriptional factor c-myc by oligonucleotide PROTAC for the treatment of hepatocellular carcinoma. Eur J Med Chem. 2024;280:116978. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116978.","journal-title":"Eur J Med Chem"},{"issue":"3","key":"798_CR117","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41580-024-00789-x","volume":"26","author":"G Pei","year":"2025","unstructured":"Pei G, Lyons H, Li P, Sabari BR. Transcription regulation by biomolecular condensates. Nat Rev Mol Cell Biol. 2025;26(3):213\u201336. https:\/\/doi.org\/10.1038\/s41580-024-00789-x.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"10","key":"798_CR118","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/s41594-024-01322-6","volume":"31","author":"J Yang","year":"2024","unstructured":"Yang J, Chung CI, Koach J, Liu H, Navalkar A, He H, et al. MYC phase separation selectively modulates the transcriptome. Nat Struct Mol Biol. 2024;31(10):1567\u201379. https:\/\/doi.org\/10.1038\/s41594-024-01322-6.","journal-title":"Nat Struct Mol Biol"},{"issue":"11","key":"798_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.107836","volume":"300","author":"X Pei","year":"2024","unstructured":"Pei X, Chen Y, Liu L, Meng L, Zhang J, Liu Y, et al. E242\u2013E261 region of MYC regulates liquid-liquid phase separation and tumor growth by providing negative charges. J Biol Chem. 2024;300(11):107836. https:\/\/doi.org\/10.1016\/j.jbc.2024.107836.","journal-title":"J Biol Chem"},{"issue":"1","key":"798_CR120","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41392-024-02070-1","volume":"10","author":"S Jeon","year":"2025","unstructured":"Jeon S, Jeon Y, Lim JY, Kim Y, Cha B, Kim W. Emerging regulatory mechanisms and functions of biomolecular condensates: implications for therapeutic targets. Signal Transduct Target Ther. 2025;10(1):4. https:\/\/doi.org\/10.1038\/s41392-024-02070-1.","journal-title":"Signal Transduct Target Ther"},{"issue":"18","key":"798_CR121","doi-asserted-by":"publisher","first-page":"11593","DOI":"10.1073\/pnas.182256799","volume":"99","author":"A Siddiqui-Jain","year":"2002","unstructured":"Siddiqui-Jain A, Grand CL, Bearss DJ, Hurley LH. Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. Proc Natl Acad Sci. 2002;99(18):11593\u20138. https:\/\/doi.org\/10.1073\/pnas.182256799.","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"798_CR122","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1021\/acs.jmedchem.0c01145","volume":"64","author":"R Chaudhuri","year":"2021","unstructured":"Chaudhuri R, Bhattacharya S, Dash J, Bhattacharya S. Recent update on targeting c-MYC G-quadruplexes by small molecules for anticancer therapeutics. J Med Chem. 2021;64(1):42\u201370. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01145.","journal-title":"J Med Chem"},{"key":"798_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2022.129016","volume":"77","author":"H Xu","year":"2022","unstructured":"Xu H, Hurley LH. A first-in-class clinical G-quadruplex-targeting drug. The bench-to-bedside translation of the fluoroquinolone QQ58 to CX-5461 (Pidnarulex). Bioorg Med Chem Lett. 2022;77:129016. https:\/\/doi.org\/10.1016\/j.bmcl.2022.129016.","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"798_CR124","doi-asserted-by":"publisher","DOI":"10.3390\/scipharm93010006","volume":"93","author":"P Thumpati","year":"2025","unstructured":"Thumpati P, Rai SN, Prajapati C, Ramakrishna K, Singh SK. Targeting c-MYC G-quadruplexes for cancer treatment with small molecules. Sci Pharm. 2025;93(1):6.","journal-title":"Sci Pharm"},{"issue":"16","key":"798_CR125","doi-asserted-by":"publisher","first-page":"5671","DOI":"10.1021\/jm200062u","volume":"54","author":"T-M Ou","year":"2011","unstructured":"Ou T-M, Lin J, Lu Y-J, Hou J-Q, Tan J-H, Chen S-H, et al. Inhibition of cell proliferation by quindoline derivative (SYUIQ-05) through its preferential interaction with c-myc promoter G-quadruplex. J Med Chem. 2011;54(16):5671\u20139. https:\/\/doi.org\/10.1021\/jm200062u.","journal-title":"J Med Chem"},{"issue":"63","key":"798_CR126","doi-asserted-by":"publisher","first-page":"8940","DOI":"10.1039\/D0CC02954H","volume":"56","author":"A Minard","year":"2020","unstructured":"Minard A, Morgan D, Raguseo F, Di Porzio A, Liano D, Jamieson AG, et al. A short peptide that preferentially binds c-MYC G-quadruplex DNA. Chem Comm. 2020;56(63):8940\u20133. https:\/\/doi.org\/10.1039\/D0CC02954H.","journal-title":"Chem Comm"},{"issue":"14","key":"798_CR127","doi-asserted-by":"publisher","first-page":"7856","DOI":"10.1093\/nar\/gkab594","volume":"49","author":"M Yang","year":"2021","unstructured":"Yang M, Carter S, Parmar S, Bume DD, Calabrese DR, Liang X, et al. Targeting a noncanonical, hairpin-containing G-quadruplex structure from the MYCN gene. Nucleic Acids Res. 2021;49(14):7856\u201369. https:\/\/doi.org\/10.1093\/nar\/gkab594.","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"798_CR128","doi-asserted-by":"publisher","first-page":"7006","DOI":"10.1021\/acs.jmedchem.3c02303","volume":"67","author":"Y Han","year":"2024","unstructured":"Han Y, Buric A, Chintareddy V, DeMoss M, Chen L, Dickerhoff J, et al. Design, synthesis, and investigation of the pharmacokinetics and anticancer activities of indenoisoquinoline derivatives that stabilize the G-quadruplex in the MYC promoter and inhibit topoisomerase I. J Med Chem. 2024;67(9):7006\u201332. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c02303.","journal-title":"J Med Chem"},{"issue":"8","key":"798_CR129","doi-asserted-by":"publisher","first-page":"5484","DOI":"10.1021\/acs.jmedchem.2c01808","volume":"66","author":"T-Y Wu","year":"2023","unstructured":"Wu T-Y, Chen X-C, Tang G-X, Shao W, Li Z-C, Chen S-B, et al. Development and characterization of benzoselenazole derivatives as potent and selective c-MYC transcription inhibitors. J Med Chem. 2023;66(8):5484\u201399. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c01808.","journal-title":"J Med Chem"},{"key":"798_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2022.134673","volume":"1275","author":"X Geng","year":"2023","unstructured":"Geng X, Zhang Y, Li S, Liu L, Yao R, Liu L, et al. Design, synthesis, and biological evaluation of novel benzimidazolyl isoxazole derivatives as potential c-Myc G4 stabilizers to suppress c-Myc transcription and myeloma growth. J Mol Struct. 2023;1275:134673. https:\/\/doi.org\/10.1016\/j.molstruc.2022.134673.","journal-title":"J Mol Struct"},{"key":"798_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117245","volume":"285","author":"F Moraca","year":"2025","unstructured":"Moraca F, Arciuolo V, Marzano S, Napolitano F, Castellano G, D\u2019Aria F, et al. Repurposing FDA-approved drugs to target G-quadruplexes in breast cancer. Eur J Med Chem. 2025;285:117245. https:\/\/doi.org\/10.1016\/j.ejmech.2025.117245.","journal-title":"Eur J Med Chem"},{"issue":"18","key":"798_CR132","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26185542","volume":"26","author":"AM Psaras","year":"2021","unstructured":"Psaras AM, Chang KT, Hao T, Brooks TA. Targeted downregulation of MYC through G-quadruplex stabilization by DNAi. Molecules. 2021;26(18):5542.","journal-title":"Molecules"},{"issue":"20","key":"798_CR133","doi-asserted-by":"publisher","first-page":"6264","DOI":"10.1158\/0008-5472.Can-13-0122-t","volume":"73","author":"MF Segura","year":"2013","unstructured":"Segura MF, Fontanals-Cirera B, Gaziel-Sovran A, Guijarro MV, Hanniford D, Zhang G, et al. BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy. Cancer Res. 2013;73(20):6264\u201376. https:\/\/doi.org\/10.1158\/0008-5472.Can-13-0122-t.","journal-title":"Cancer Res"},{"issue":"5","key":"798_CR134","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.molcel.2014.05.016","volume":"54","author":"J Shi","year":"2014","unstructured":"Shi J, Vakoc CR. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol Cell. 2014;54(5):728\u201336. https:\/\/doi.org\/10.1016\/j.molcel.2014.05.016.","journal-title":"Mol Cell"},{"key":"798_CR135","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026674","author":"Y Xu","year":"2017","unstructured":"Xu Y, Vakoc CR. Targeting cancer cells with BET bromodomain inhibitors. Cold Spring Harb Perspect Med. 2017. https:\/\/doi.org\/10.1101\/cshperspect.a026674.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"40","key":"798_CR136","doi-asserted-by":"publisher","first-page":"16669","DOI":"10.1073\/pnas.1108190108","volume":"108","author":"JA Mertz","year":"2011","unstructured":"Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci USA. 2011;108(40):16669\u201374. https:\/\/doi.org\/10.1073\/pnas.1108190108.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7327","key":"798_CR137","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","volume":"468","author":"P Filippakopoulos","year":"2010","unstructured":"Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067\u201373. https:\/\/doi.org\/10.1038\/nature09504.","journal-title":"Nature"},{"issue":"7327","key":"798_CR138","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/nature09589","volume":"468","author":"E Nicodeme","year":"2010","unstructured":"Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung C-w, et al. Suppression of inflammation by a synthetic histone mimic. Nature. 2010;468(7327):1119\u201323. https:\/\/doi.org\/10.1038\/nature09589.","journal-title":"Nature"},{"issue":"7370","key":"798_CR139","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nature10334","volume":"478","author":"J Zuber","year":"2011","unstructured":"Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011;478(7370):524\u20138. https:\/\/doi.org\/10.1038\/nature10334.","journal-title":"Nature"},{"issue":"7586","key":"798_CR140","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nature16508","volume":"529","author":"S Shu","year":"2016","unstructured":"Shu S, Lin CY, He HH, Witwicki RM, Tabassum DP, Roberts JM, et al. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature. 2016;529(7586):413\u20137. https:\/\/doi.org\/10.1038\/nature16508.","journal-title":"Nature"},{"issue":"9","key":"798_CR141","doi-asserted-by":"publisher","first-page":"e2365","DOI":"10.1038\/cddis.2016.271","volume":"7","author":"O Klingbeil","year":"2016","unstructured":"Klingbeil O, Lesche R, Gelato KA, Haendler B, Lejeune P. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents. Cell Death Dis. 2016;7(9):e2365. https:\/\/doi.org\/10.1038\/cddis.2016.271.","journal-title":"Cell Death Dis"},{"issue":"11","key":"798_CR142","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.18632\/oncotarget.1534","volume":"4","author":"A Henssen","year":"2013","unstructured":"Henssen A, Thor T, Odersky A, Heukamp L, El-Hindy N, Beckers A, et al. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. Oncotarget. 2013;4(11):2080\u201395. https:\/\/doi.org\/10.18632\/oncotarget.1534.","journal-title":"Oncotarget"},{"issue":"7","key":"798_CR143","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1158\/1078-0432.Ccr-14-1561","volume":"21","author":"M Boi","year":"2015","unstructured":"Boi M, Gaudio E, Bonetti P, Kwee I, Bernasconi E, Tarantelli C, et al. The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs. Clin Cancer Res. 2015;21(7):1628\u201338. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-1561.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"798_CR144","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1182\/blood-2013-01-478420","volume":"123","author":"A Chaidos","year":"2014","unstructured":"Chaidos A, Caputo V, Gouvedenou K, Liu B, Marigo I, Chaudhry MS, et al. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood. 2014;123(5):697\u2013705. https:\/\/doi.org\/10.1182\/blood-2013-01-478420.","journal-title":"Blood"},{"issue":"8","key":"798_CR145","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0072967","volume":"8","author":"A Wyce","year":"2013","unstructured":"Wyce A, Ganji G, Smitheman KN, Chung CW, Korenchuk S, Bai Y, et al. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models. PLoS\u00a0One. 2013;8(8):e72967. https:\/\/doi.org\/10.1371\/journal.pone.0072967.","journal-title":"PLoS\u00a0One"},{"key":"798_CR146","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.canlet.2017.02.021","volume":"394","author":"AS Leal","year":"2017","unstructured":"Leal AS, Williams CR, Royce DB, Pioli PA, Sporn MB, Liby KT. Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer. Cancer Lett. 2017;394:76\u201387. https:\/\/doi.org\/10.1016\/j.canlet.2017.02.021.","journal-title":"Cancer Lett"},{"issue":"19","key":"798_CR147","doi-asserted-by":"publisher","first-page":"17698","DOI":"10.18632\/oncotarget.4131","volume":"6","author":"MM Coud\u00e9","year":"2015","unstructured":"Coud\u00e9 MM, Braun T, Berrou J, Dupont M, Bertrand S, Masse A, et al. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells. Oncotarget. 2015;6(19):17698\u2013712. https:\/\/doi.org\/10.18632\/oncotarget.4131.","journal-title":"Oncotarget"},{"issue":"10","key":"798_CR148","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1158\/1078-0432.Ccr-15-1449","volume":"22","author":"A Henssen","year":"2016","unstructured":"Henssen A, Althoff K, Odersky A, Beckers A, Koche R, Speleman F, et al. Targeting MYCN-driven transcription by BET-bromodomain inhibition. Clin Cancer Res. 2016;22(10):2470\u201381. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-1449.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"798_CR149","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/ijc.30412","volume":"140","author":"R V\u00e1zquez","year":"2017","unstructured":"V\u00e1zquez R, Licandro SA, Astorgues-Xerri L, Lettera E, Panini N, Romano M, et al. Promising in vivo efficacy of the BET bromodomain inhibitor OTX015\/MK-8628 in malignant pleural mesothelioma xenografts. Int J Cancer. 2017;140(1):197\u2013207. https:\/\/doi.org\/10.1002\/ijc.30412.","journal-title":"Int J Cancer"},{"issue":"20","key":"798_CR150","doi-asserted-by":"publisher","first-page":"8369","DOI":"10.1021\/acs.jmedchem.7b00746","volume":"60","author":"KF McDaniel","year":"2017","unstructured":"McDaniel KF, Wang L, Soltwedel T, Fidanze SD, Hasvold LA, Liu D, et al. Discovery of N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075\/Mivebresib), a potent and orally available bromodomain and extraterminal domain (BET) family bromodomain inhibitor. J Med Chem. 2017;60(20):8369\u201384. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b00746.","journal-title":"J Med Chem"},{"issue":"2","key":"798_CR151","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ccr.2014.01.028","volume":"25","author":"J Shi","year":"2014","unstructured":"Shi J, Wang Y, Zeng L, Wu Y, Deng J, Zhang Q, et al. Disrupting the interaction of BRD4 with diacetylated twist suppresses tumorigenesis in basal-like breast cancer. Cancer Cell. 2014;25(2):210\u201325. https:\/\/doi.org\/10.1016\/j.ccr.2014.01.028.","journal-title":"Cancer Cell"},{"issue":"2","key":"798_CR152","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s13402-020-00578-6","volume":"44","author":"A Andrikopoulou","year":"2021","unstructured":"Andrikopoulou A, Liontos M, Koutsoukos K, Dimopoulos M-A, Zagouri F. Clinical perspectives of BET inhibition in ovarian cancer. Cell Oncol. 2021;44(2):237\u201349. https:\/\/doi.org\/10.1007\/s13402-020-00578-6.","journal-title":"Cell Oncol"},{"issue":"6489","key":"798_CR153","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1126\/science.aaz8455","volume":"368","author":"O Gilan","year":"2020","unstructured":"Gilan O, Rioja I, Knezevic K, Bell MJ, Yeung MM, Harker NR, et al. Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. Science. 2020;368(6489):387\u201394. https:\/\/doi.org\/10.1126\/science.aaz8455.","journal-title":"Science"},{"key":"798_CR154","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.574525","volume":"10","author":"Z Li","year":"2020","unstructured":"Li Z, Lim SL, Tao Y, Li X, Xie Y, Yang C, et al. PROTAC bromodomain inhibitor ARV-825 displays anti-tumor activity in neuroblastoma by repressing expression of MYCN or c-Myc. Front Oncol. 2020;10:574525. https:\/\/doi.org\/10.3389\/fonc.2020.574525.","journal-title":"Front Oncol"},{"key":"798_CR155","doi-asserted-by":"publisher","first-page":"1610447","DOI":"10.3389\/pore.2022.1610447","volume":"28","author":"K Zhang","year":"2022","unstructured":"Zhang K, Gao L, Wang J, Chu X, Zhang Z, Zhang Y, et al. A novel BRD family PROTAC inhibitor dBET1 exerts great anti-cancer effects by targeting c-MYC in acute myeloid leukemia cells. Pathol Oncol Res. 2022;28:1610447. https:\/\/doi.org\/10.3389\/pore.2022.1610447.","journal-title":"Pathol Oncol Res"},{"issue":"3","key":"798_CR156","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1039\/C3MD00285C","volume":"5","author":"SJ Atkinson","year":"2014","unstructured":"Atkinson SJ, Soden PE, Angell DC, Bantscheff M, Chung C-w, Giblin KA, et al. The structure based design of dual HDAC\/BET inhibitors as novel epigenetic probes. MedChemComm. 2014;5(3):342\u201351. https:\/\/doi.org\/10.1039\/C3MD00285C.","journal-title":"MedChemComm"},{"issue":"7","key":"798_CR157","doi-asserted-by":"publisher","first-page":"E1072","DOI":"10.1073\/pnas.1613091114","volume":"114","author":"FH Andrews","year":"2017","unstructured":"Andrews FH, Singh AR, Joshi S, Smith CA, Morales GA, Garlich JR, et al. Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis. Proc Natl Acad Sci USA. 2017;114(7):E1072\u201380. https:\/\/doi.org\/10.1073\/pnas.1613091114.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"20","key":"798_CR158","doi-asserted-by":"publisher","first-page":"5338","DOI":"10.1158\/1078-0432.Ccr-20-1707","volume":"26","author":"RR Aggarwal","year":"2020","unstructured":"Aggarwal RR, Schweizer MT, Nanus DM, Pantuck AJ, Heath EI, Campeau E, et al. A phase Ib\/IIa study of the pan-BET Inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2020;26(20):5338\u201347. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-1707.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"798_CR159","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1038\/s41388-018-0150-2","volume":"37","author":"D Gerlach","year":"2018","unstructured":"Gerlach D, Tontsch-Grunt U, Baum A, Popow J, Scharn D, Hofmann MH, et al. The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML. Oncogene. 2018;37(20):2687\u2013701. https:\/\/doi.org\/10.1038\/s41388-018-0150-2.","journal-title":"Oncogene"},{"issue":"4","key":"798_CR160","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(16)00021-1","volume":"3","author":"S Amorim","year":"2016","unstructured":"Amorim S, Stathis A, Gleeson M, Iyengar S, Magarotto V, Leleu X, et al. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. Lancet Haematol. 2016;3(4):e196\u2013204. https:\/\/doi.org\/10.1016\/S2352-3026(16)00021-1.","journal-title":"Lancet Haematol."},{"issue":"15_suppl","key":"798_CR161","doi-asserted-by":"publisher","first-page":"7030","DOI":"10.1200\/JCO.2019.37.15_suppl.7030","volume":"37","author":"O Odenike","year":"2019","unstructured":"Odenike O, Wolff JE, Borthakur G, Aldoss IT, Rizzieri D, Prebet T, et al. Results from the first-in-human study of mivebresib (ABBV-075), a pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed\/refractory acute myeloid leukemia. J Clin Oncol. 2019;37(15_suppl):7030. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.7030.","journal-title":"J Clin Oncol"},{"issue":"1","key":"798_CR162","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.bbagrm.2012.08.013","volume":"1829","author":"M Heidemann","year":"2013","unstructured":"Heidemann M, Hintermair C, Vo\u00df K, Eick D. Dynamic phosphorylation patterns of RNA polymerase II CTD during transcription. Biochim Biophys Acta Gene Regul Mech. 2013;1829(1):55\u201362. https:\/\/doi.org\/10.1016\/j.bbagrm.2012.08.013.","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"issue":"590","key":"798_CR163","doi-asserted-by":"publisher","first-page":"eaav7259","DOI":"10.1126\/scisignal.aav7259","volume":"12","author":"DR Blake","year":"2019","unstructured":"Blake DR, Vaseva AV, Hodge RG, Kline MP, Gilbert TSK, Tyagi V, et al. Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer. Sci Signal. 2019;12(590):eaav7259. https:\/\/doi.org\/10.1126\/scisignal.aav7259.","journal-title":"Sci Signal."},{"issue":"1","key":"798_CR164","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.cell.2015.08.063","volume":"163","author":"Y Wang","year":"2015","unstructured":"Wang Y, Zhang T, Kwiatkowski N, Abraham Brian J, Lee Tong I, Xie S, et al. CDK7-Dependent transcriptional addiction in triple-negative breast cancer. Cell. 2015;163(1):174\u201386. https:\/\/doi.org\/10.1016\/j.cell.2015.08.063.","journal-title":"Cell"},{"issue":"1","key":"798_CR165","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ccell.2019.11.003","volume":"37","author":"H Zhang","year":"2020","unstructured":"Zhang H, Christensen CL, Dries R, Oser MG, Deng J, Diskin B, et al. CDK7 inhibition potentiates genome instability triggering anti-tumor immunity in small cell lung cancer. Cancer Cell. 2020;37(1):37-54.e9. https:\/\/doi.org\/10.1016\/j.ccell.2019.11.003.","journal-title":"Cancer Cell"},{"issue":"5","key":"798_CR166","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.cell.2014.10.024","volume":"159","author":"E Chipumuro","year":"2014","unstructured":"Chipumuro E, Marco E, Christensen Camilla L, Kwiatkowski N, Zhang T, Hatheway Clark M, et al. CDK7 Inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell. 2014;159(5):1126\u201339. https:\/\/doi.org\/10.1016\/j.cell.2014.10.024.","journal-title":"Cell"},{"issue":"7511","key":"798_CR167","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nature13393","volume":"511","author":"N Kwiatkowski","year":"2014","unstructured":"Kwiatkowski N, Zhang T, Rahl PB, Abraham BJ, Reddy J, Ficarro SB, et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 2014;511(7511):616\u201320. https:\/\/doi.org\/10.1038\/nature13393.","journal-title":"Nature"},{"issue":"10","key":"798_CR168","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/nchembio.2166","volume":"12","author":"T Zhang","year":"2016","unstructured":"Zhang T, Kwiatkowski N, Olson CM, Dixon-Clarke SE, Abraham BJ, Greifenberg AK, et al. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat Chem Biol. 2016;12(10):876\u201384. https:\/\/doi.org\/10.1038\/nchembio.2166.","journal-title":"Nat Chem Biol"},{"issue":"3","key":"798_CR169","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s10555-020-09885-8","volume":"39","author":"GP Sava","year":"2020","unstructured":"Sava GP, Fan H, Coombes RC, Buluwela L, Ali S. CDK7 inhibitors as anticancer drugs. Cancer Metastasis Rev. 2020;39(3):805\u201323. https:\/\/doi.org\/10.1007\/s10555-020-09885-8.","journal-title":"Cancer Metastasis Rev"},{"issue":"Supplement 1","key":"798_CR170","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1182\/blood-2018-99-116634","volume":"132","author":"L Guo","year":"2018","unstructured":"Guo L, Li J, Fang S, Lee M, Zeng H, Li T, et al. Synthetic lethality of combinatory inhibition of BET and CDK7 in BET(i) resistant leukemia cells. Blood. 2018;132(Supplement 1):1354. https:\/\/doi.org\/10.1182\/blood-2018-99-116634.","journal-title":"Blood"},{"issue":"10","key":"798_CR171","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1093\/neuonc\/noaf121","volume":"27","author":"LM Sobral","year":"2025","unstructured":"Sobral LM, Walker FM, Madhavan K, Janko E, Donthula S, Danis E, et al. Targeting processive transcription for Myc-driven circuitry in medulloblastoma. Neuro Oncol. 2025;27(10):2697\u2013710. https:\/\/doi.org\/10.1093\/neuonc\/noaf121.","journal-title":"Neuro Oncol"},{"issue":"1","key":"798_CR172","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2023.2219470","volume":"24","author":"L Xiao","year":"2023","unstructured":"Xiao L, Liu Y, Chen H, Shen L. Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments. Cancer Biol Ther. 2023;24(1):2219470. https:\/\/doi.org\/10.1080\/15384047.2023.2219470.","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"798_CR173","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nbt1358","volume":"26","author":"MW Karaman","year":"2008","unstructured":"Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26(1):127\u201332. https:\/\/doi.org\/10.1038\/nbt1358.","journal-title":"Nat Biotechnol"},{"key":"798_CR174","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.06535","volume":"4","author":"H Lu","year":"2015","unstructured":"Lu H, Xue Y, Yu GK, Arias C, Lin J, Fong S, et al. Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism. Elife. 2015;4:e06535. https:\/\/doi.org\/10.7554\/eLife.06535.","journal-title":"Elife"},{"key":"798_CR175","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.bbrc.2023.05.114","volume":"671","author":"R Liu","year":"2023","unstructured":"Liu R. Brd4-dependent CDK9 expression induction upon sustained pharmacological inhibition of P-TEFb kinase activity. Biochem Biophys Res Commun. 2023;671:75\u20139. https:\/\/doi.org\/10.1016\/j.bbrc.2023.05.114.","journal-title":"Biochem Biophys Res Commun"},{"issue":"20","key":"798_CR176","doi-asserted-by":"publisher","first-page":"21172","DOI":"10.1021\/acs.jmedchem.5c01111","volume":"68","author":"L Ma","year":"2025","unstructured":"Ma L, Xie L, Wang Y, Guan X, Zhang Y, Guo H, et al. Discovery of dCDK9-202 as a highly potent and selective PROTAC CDK9 degrader with strong in vivo antitumor activity. J Med Chem. 2025;68(20):21172\u201386. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c01111.","journal-title":"J Med Chem"},{"issue":"4","key":"798_CR177","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.chembiol.2025.03.001","volume":"32","author":"MA Toure","year":"2025","unstructured":"Toure MA, Motoyama K, Xiang Y, Urgiles J, Kabinger F, Koglin A-S, et al. Targeted degradation of CDK9 potently disrupts the MYC-regulated network. Cell Chem Biol. 2025;32(4):542-55.e10. https:\/\/doi.org\/10.1016\/j.chembiol.2025.03.001.","journal-title":"Cell Chem Biol"},{"issue":"33","key":"798_CR178","doi-asserted-by":"publisher","first-page":"13339","DOI":"10.1073\/pnas.1303781110","volume":"110","author":"K Feoktistova","year":"2013","unstructured":"Feoktistova K, Tuvshintogs E, Do A, Fraser CS. Human eIF4E promotes mRNA restructuring by stimulating eIF4A helicase activity. Proc Natl Acad Sci U S A. 2013;110(33):13339\u201344. https:\/\/doi.org\/10.1073\/pnas.1303781110.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"798_CR179","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1158\/0008-5472.Can-22-0945","volume":"83","author":"D Kuzuoglu-Ozturk","year":"2023","unstructured":"Kuzuoglu-Ozturk D, Aksoy O, Schmidt C, Lea R, Larson JD, Phelps RRL, et al. N-myc-mediated translation control is a therapeutic vulnerability in medulloblastoma. Cancer Res. 2023;83(1):130\u201340. https:\/\/doi.org\/10.1158\/0008-5472.Can-22-0945.","journal-title":"Cancer Res"},{"issue":"4","key":"798_CR180","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1172\/JCI44145","volume":"121","author":"SA Wander","year":"2011","unstructured":"Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Investig. 2011;121(4):1231\u201341. https:\/\/doi.org\/10.1172\/JCI44145.","journal-title":"J Clin Investig"},{"key":"798_CR181","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2024.119145","volume":"339","author":"J Song","year":"2025","unstructured":"Song J, Liu W, Xiao X, Song J, Wang C, Gajendran B, et al. Rocaglamide reprograms glucose metabolism in erythroleukemic cells via c-MYC transcriptional regulation of TXNIP and HK2. J Ethnopharmacol. 2025;339:119145. https:\/\/doi.org\/10.1016\/j.jep.2024.119145.","journal-title":"J Ethnopharmacol"},{"issue":"2","key":"798_CR182","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1182\/blood-2009-02-205153","volume":"114","author":"S Assouline","year":"2009","unstructured":"Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, Amri A, et al. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood. 2009;114(2):257\u201360. https:\/\/doi.org\/10.1182\/blood-2009-02-205153.","journal-title":"Blood"},{"issue":"6","key":"798_CR183","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1038\/s41416-020-01205-9","volume":"124","author":"L-o Herzog","year":"2021","unstructured":"Herzog L-o, Walters B, Buono R, Lee JS, Mallya S, Fung A, et al. Targeting eIF4F translation initiation complex with SBI-756 sensitises B lymphoma cells to venetoclax. Br J Cancer. 2021;124(6):1098\u2013109. https:\/\/doi.org\/10.1038\/s41416-020-01205-9.","journal-title":"Br J Cancer"},{"issue":"10","key":"798_CR184","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101731","volume":"5","author":"L He","year":"2024","unstructured":"He L, Zhang X, Shi F, Zhang H, Chen Y, Sun K, et al. Reprograming immunosuppressive microenvironment by eIF4G1 targeting to eradicate pancreatic ductal adenocarcinoma. Cell Rep Med. 2024;5(10):101731. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101731.","journal-title":"Cell Rep Med"},{"issue":"3","key":"798_CR185","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/ncb1224","volume":"7","author":"C Grandori","year":"2005","unstructured":"Grandori C, Gomez-Roman N, Felton-Edkins ZA, Ngouenet C, Galloway DA, Eisenman RN, et al. c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I. Nat Cell Biol. 2005;7(3):311\u20138. https:\/\/doi.org\/10.1038\/ncb1224.","journal-title":"Nat Cell Biol"},{"key":"798_CR186","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a018408","author":"KJ Campbell","year":"2014","unstructured":"Campbell KJ, White RJ. MYC regulation of cell growth through control of transcription by RNA polymerases I and III. Cold Spring Harb Perspect Med. 2014. https:\/\/doi.org\/10.1101\/cshperspect.a018408.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"12","key":"798_CR187","first-page":"3199","volume":"8","author":"M Henriksson","year":"1993","unstructured":"Henriksson M, Bakardjiev A, Klein G, L\u00fcscher B. Phosphorylation sites mapping in the N-terminal domain of c-myc modulate its transforming potential. Oncogene. 1993;8(12):3199\u2013209.","journal-title":"Oncogene"},{"issue":"1","key":"798_CR188","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1073\/pnas.0900121106","volume":"107","author":"P Hydbring","year":"2010","unstructured":"Hydbring P, Bahram F, Su Y, Tronnersjo S, Hogstrand K, von der Lehr N, et al. Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation. Proc Natl Acad Sci USA. 2010;107(1):58\u201363. https:\/\/doi.org\/10.1073\/pnas.0900121106.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"23","key":"798_CR189","doi-asserted-by":"publisher","first-page":"15601","DOI":"10.1074\/jbc.M800987200","volume":"283","author":"HR Seo","year":"2008","unstructured":"Seo HR, Kim J, Bae S, Soh J-W, Lee Y-S. Cdk5-mediated phosphorylation of c-Myc on Ser-62 is essential in transcriptional activation of cyclin B1 by cyclin G1*. J Biol Chem. 2008;283(23):15601\u201310. https:\/\/doi.org\/10.1074\/jbc.M800987200.","journal-title":"J Biol Chem"},{"issue":"19","key":"798_CR190","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1101\/gad.836800","volume":"14","author":"R Sears","year":"2000","unstructured":"Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 2000;14(19):2501\u201314. https:\/\/doi.org\/10.1101\/gad.836800.","journal-title":"Genes Dev"},{"issue":"51","key":"798_CR191","doi-asserted-by":"publisher","first-page":"51606","DOI":"10.1074\/jbc.M310722200","volume":"278","author":"MA Gregory","year":"2003","unstructured":"Gregory MA, Qi Y, Hann SR. Phosphorylation by glycogen synthase kinase-3 controls c-Myc proteolysis and subnuclear localization*. J Biol Chem. 2003;278(51):51606\u201312. https:\/\/doi.org\/10.1074\/jbc.M310722200.","journal-title":"J Biol Chem"},{"issue":"4","key":"798_CR192","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/ncb1110","volume":"6","author":"E Yeh","year":"2004","unstructured":"Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G, et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol. 2004;6(4):308\u201318. https:\/\/doi.org\/10.1038\/ncb1110.","journal-title":"Nat Cell Biol"},{"issue":"24","key":"798_CR193","doi-asserted-by":"publisher","first-page":"9085","DOI":"10.1073\/pnas.0402770101","volume":"101","author":"M Welcker","year":"2004","unstructured":"Welcker M, Orian A, Jin J, Grim JA, Harper JW, Eisenman RN, et al. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci USA. 2004;101(24):9085\u201390. https:\/\/doi.org\/10.1073\/pnas.0402770101.","journal-title":"Proc Natl Acad Sci USA"},{"key":"798_CR194","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00224","author":"GM Cohn","year":"2020","unstructured":"Cohn GM, Liefwalker DF, Langer EM, Sears RC. PIN1 provides dynamic control of MYC in response to extrinsic signals. Front Cell Dev Biol. 2020. https:\/\/doi.org\/10.3389\/fcell.2020.00224.","journal-title":"Front Cell Dev Biol."},{"issue":"5","key":"798_CR195","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nm.3839","volume":"21","author":"S Wei","year":"2015","unstructured":"Wei S, Kozono S, Kats L, Nechama M, Li W, Guarnerio J, et al. Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer. Nat Med. 2015;21(5):457\u201366. https:\/\/doi.org\/10.1038\/nm.3839.","journal-title":"Nat Med"},{"issue":"9","key":"798_CR196","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41589-021-00786-7","volume":"17","author":"C Dubiella","year":"2021","unstructured":"Dubiella C, Pinch BJ, Koikawa K, Zaidman D, Poon E, Manz TD, et al. Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo. Nat Chem Biol. 2021;17(9):954\u201363. https:\/\/doi.org\/10.1038\/s41589-021-00786-7.","journal-title":"Nat Chem Biol"},{"issue":"1","key":"798_CR197","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-025-03560-y","volume":"44","author":"F Sarais","year":"2025","unstructured":"Sarais F, Krempien F, Koehn C, Brewing L, Classen CF, Walter M, et al. Targeting PP2A in cancer: an underrated option. J Exp Clin Cancer Res. 2025;44(1):295. https:\/\/doi.org\/10.1186\/s13046-025-03560-y.","journal-title":"J Exp Clin Cancer Res"},{"key":"798_CR198","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118077","volume":"260","author":"Y Zhong","year":"2020","unstructured":"Zhong Y, Tian F, Ma H, Wang H, Yang W, Liu Z, et al. FTY720 induces ferroptosis and autophagy via PP2A\/AMPK pathway in multiple myeloma cells. Life Sci. 2020;260:118077. https:\/\/doi.org\/10.1016\/j.lfs.2020.118077.","journal-title":"Life Sci"},{"issue":"11","key":"798_CR199","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1182\/blood-2013-03-492181","volume":"122","author":"JJ Oaks","year":"2013","unstructured":"Oaks JJ, Santhanam R, Walker CJ, Roof S, Harb JG, Ferenchak G, et al. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood. 2013;122(11):1923\u201334. https:\/\/doi.org\/10.1182\/blood-2013-03-492181.","journal-title":"Blood"},{"issue":"4","key":"798_CR200","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.3892\/ijo.2020.5114","volume":"57","author":"MA Kolodziej","year":"2020","unstructured":"Kolodziej MA, Al Barim B, Nagl J, Weigand MA, Uhl E, Uhle F, et al. Sphingosine-1-phosphate analogue FTY720 exhibits a potent anti-proliferative effect on glioblastoma cells. Int J Oncol. 2020;57(4):1039\u201346. https:\/\/doi.org\/10.3892\/ijo.2020.5114.","journal-title":"Int J Oncol"},{"issue":"450","key":"798_CR201","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaq1093","volume":"10","author":"O Kauko","year":"2018","unstructured":"Kauko O, O\u2019Connor CM, Kulesskiy E, Sangodkar J, Aakula A, Izadmehr S, et al. PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. Sci Transl Med. 2018;10(450):eaaq1093. https:\/\/doi.org\/10.1126\/scitranslmed.aaq1093.","journal-title":"Sci Transl Med"},{"issue":"7677","key":"798_CR202","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature24451","volume":"550","author":"AP Turnbull","year":"2017","unstructured":"Turnbull AP, Ioannidis S, Krajewski WW, Pinto-Fernandez A, Heride C, Martin ACL, et al. Molecular basis of USP7 inhibition by selective small-molecule inhibitors. Nature. 2017;550(7677):481\u20136. https:\/\/doi.org\/10.1038\/nature24451.","journal-title":"Nature"},{"issue":"1","key":"798_CR203","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1038\/s41467-025-56981-w","volume":"16","author":"Y-L Miao","year":"2025","unstructured":"Miao Y-L, Fan F, Cheng Y-J, Jia L, Song S-S, Huan X-J, et al. USP7 V517F mutation as a mechanism of inhibitor resistance. Nat Commun. 2025;16(1):2526. https:\/\/doi.org\/10.1038\/s41467-025-56981-w.","journal-title":"Nat Commun"},{"issue":"10","key":"798_CR204","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/nm.4180","volume":"22","author":"O Tavana","year":"2016","unstructured":"Tavana O, Li D, Dai C, Lopez G, Banerjee D, Kon N, et al. HAUSP deubiquitinates and stabilizes N-Myc in neuroblastoma. Nat Med. 2016;22(10):1180\u20136. https:\/\/doi.org\/10.1038\/nm.4180.","journal-title":"Nat Med"},{"issue":"1","key":"798_CR205","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-1109-2","volume":"20","author":"W Zhang","year":"2020","unstructured":"Zhang W, Zhang J, Xu C, Zhang S, Bian S, Jiang F, et al. Ubiquitin-specific protease 7 is a drug-able target that promotes hepatocellular carcinoma and chemoresistance. Cancer Cell Int. 2020;20(1):28. https:\/\/doi.org\/10.1186\/s12935-020-1109-2.","journal-title":"Cancer Cell Int"},{"issue":"3","key":"798_CR206","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.molcel.2016.09.016","volume":"64","author":"D Xiao","year":"2016","unstructured":"Xiao D, Yue M, Su H, Ren P, Jiang J, Li F, et al. Polo-like kinase-1 regulates Myc stabilization and activates a feedforward circuit promoting tumor cell survival. Mol Cell. 2016;64(3):493\u2013506. https:\/\/doi.org\/10.1016\/j.molcel.2016.09.016.","journal-title":"Mol Cell"},{"key":"798_CR207","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1602752","author":"W Wang","year":"2025","unstructured":"Wang W, Zhao R, Wang Y, Pan L, Luan F, Fu G. PLK1 in cancer therapy: a comprehensive review of immunomodulatory mechanisms and therapeutic opportunities. Front Immunol. 2025. https:\/\/doi.org\/10.3389\/fimmu.2025.1602752.","journal-title":"Front Immunol"},{"key":"798_CR208","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.canlet.2019.11.027","volume":"469","author":"W Zhang","year":"2020","unstructured":"Zhang W, Ge H, Jiang Y, Huang R, Wu Y, Wang D, et al. Combinational therapeutic targeting of BRD4 and CDK7 synergistically induces anticancer effects in head and neck squamous cell carcinoma. Cancer Lett. 2020;469:510\u201323. https:\/\/doi.org\/10.1016\/j.canlet.2019.11.027.","journal-title":"Cancer Lett"},{"issue":"31","key":"798_CR209","doi-asserted-by":"publisher","first-page":"12968","DOI":"10.1073\/pnas.0901418106","volume":"106","author":"JJ Molenaar","year":"2009","unstructured":"Molenaar JJ, Ebus ME, Geerts D, Koster J, Lamers F, Valentijn LJ, et al. Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Proc Natl Acad Sci USA. 2009;106(31):12968\u201373. https:\/\/doi.org\/10.1073\/pnas.0901418106.","journal-title":"Proc Natl Acad Sci USA"},{"key":"798_CR210","doi-asserted-by":"publisher","DOI":"10.1080\/15384101.2020.1855740","author":"W Bazzar","year":"2020","unstructured":"Bazzar W, Bocci M, Hejll E, H\u00f6gqvist Tabor V, Hydbring P, Grandien A, et al. Pharmacological inactivation of CDK2 inhibits MYC\/BCL-XL-driven leukemia in vivo through induction of cellular senescence. Cell Cycle. 2020. https:\/\/doi.org\/10.1080\/15384101.2020.1855740.","journal-title":"Cell Cycle"},{"issue":"1","key":"798_CR211","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-026-38123-4","volume":"16","author":"M Alzrigat","year":"2026","unstructured":"Alzrigat M, Mahmoud L, Top\u00e7u AN, Valenti M, Zhang L, Veen P, et al. CDK2 inhibition promotes neuronal differentiation in neuroblastoma. Sci Rep. 2026;16(1):5255. https:\/\/doi.org\/10.1038\/s41598-026-38123-4.","journal-title":"Sci Rep"},{"issue":"22","key":"798_CR212","doi-asserted-by":"publisher","first-page":"5100","DOI":"10.1158\/1078-0432.Ccr-15-0313","volume":"21","author":"ME Dolman","year":"2015","unstructured":"Dolman ME, Poon E, Ebus ME, den Hartog IJ, van Noesel CJ, Jamin Y, et al. Cyclin-dependent kinase inhibitor AT7519 as a potential drug for MYCN-dependent neuroblastoma. Clin Cancer Res. 2015;21(22):5100\u20139. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-0313.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"798_CR213","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/s1470-2045(22)00694-5","volume":"24","author":"SRD Johnston","year":"2023","unstructured":"Johnston SRD, Toi M, O\u2019Shaughnessy J, Rastogi P, Campone M, Neven P, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24(1):77\u201390. https:\/\/doi.org\/10.1016\/s1470-2045(22)00694-5.","journal-title":"Lancet Oncol"},{"issue":"11","key":"798_CR214","doi-asserted-by":"publisher","first-page":"5875","DOI":"10.1172\/jci134132","volume":"130","author":"E Poon","year":"2020","unstructured":"Poon E, Liang T, Jamin Y, Walz S, Kwok C, Hakkert A, et al. Orally bioavailable CDK9\/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma. J Clin Investig. 2020;130(11):5875\u201392. https:\/\/doi.org\/10.1172\/jci134132.","journal-title":"J Clin Investig"},{"issue":"1","key":"798_CR215","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41420-025-02637-z","volume":"11","author":"F Shokraie","year":"2025","unstructured":"Shokraie F, Lechermeier L, Bordihn P, Kaps P, M\u00f6ller S, Schulz AS, et al. CDK inhibitors promote neuroblastoma cell differentiation and increase sensitivity to retinoic acid-a promising combination strategy for therapeutic intervention. Cell Death Discov. 2025;11(1):363. https:\/\/doi.org\/10.1038\/s41420-025-02637-z.","journal-title":"Cell Death Discov."},{"issue":"19","key":"798_CR216","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1016\/j.devcel.2023.08.028","volume":"58","author":"KM Ferguson","year":"2023","unstructured":"Ferguson KM, Gillen SL, Chaytor L, Poon E, Marcos D, Gomez RL, et al. Palbociclib releases the latent differentiation capacity of neuroblastoma cells. Dev Cell. 2023;58(19):1967-82.e8. https:\/\/doi.org\/10.1016\/j.devcel.2023.08.028.","journal-title":"Dev Cell"},{"issue":"3","key":"798_CR217","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s10549-018-05125-4","volume":"174","author":"HS Rugo","year":"2019","unstructured":"Rugo HS, Finn RS, Di\u00e9ras V, Ettl J, Lipatov O, Joy AA, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat. 2019;174(3):719\u201329. https:\/\/doi.org\/10.1007\/s10549-018-05125-4.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"798_CR218","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1002\/med.22024","volume":"44","author":"X Chang","year":"2024","unstructured":"Chang X, Qu F, Li C, Zhang J, Zhang Y, Xie Y, et al. Development and therapeutic potential of GSPT1 molecular glue degraders: a medicinal chemistry perspective. Med Res Rev. 2024;44(4):1727\u201367. https:\/\/doi.org\/10.1002\/med.22024.","journal-title":"Med Res Rev"},{"issue":"12","key":"798_CR219","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1016\/j.celrep.2017.11.090","volume":"21","author":"G B\u00fcchel","year":"2017","unstructured":"B\u00fcchel G, Carstensen A, Mak KY, Roeschert I, Leen E, Sumara O, et al. Association with Aurora-A controls N-MYC-dependent promoter escape and pause release of RNA polymerase II during the cell cycle. Cell Rep. 2017;21(12):3483\u201397. https:\/\/doi.org\/10.1016\/j.celrep.2017.11.090.","journal-title":"Cell Rep"},{"issue":"1","key":"798_CR220","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.Cd-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31\u201346. https:\/\/doi.org\/10.1158\/2159-8290.Cd-21-1059.","journal-title":"Cancer Discov"},{"issue":"1-2","key":"798_CR221","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.drup.2012.01.008","volume":"15","author":"RH Wilting","year":"2012","unstructured":"Wilting RH, Dannenberg JH. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. Drug Resist Updat. 2012;15(1\u20132):21\u201338. https:\/\/doi.org\/10.1016\/j.drup.2012.01.008.","journal-title":"Drug Resist Updat"},{"issue":"1","key":"798_CR222","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-024-01803-z","volume":"10","author":"X Yu","year":"2024","unstructured":"Yu X, Zhao H, Wang R, Chen Y, Ouyang X, Li W, et al. Cancer epigenetics: from laboratory studies and clinical trials to precision medicine. Cell Death Discov. 2024;10(1):28. https:\/\/doi.org\/10.1038\/s41420-024-01803-z.","journal-title":"Cell Death Discov"},{"issue":"1","key":"798_CR223","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10555-025-10253-7","volume":"44","author":"A Suraweera","year":"2025","unstructured":"Suraweera A, O\u2019Byrne KJ, Richard DJ. Epigenetic drugs in cancer therapy. Cancer Metastasis Rev. 2025;44(1):37. https:\/\/doi.org\/10.1007\/s10555-025-10253-7.","journal-title":"Cancer Metastasis Rev"},{"issue":"4","key":"798_CR224","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.cell.2016.12.013","volume":"168","author":"JE Bradner","year":"2017","unstructured":"Bradner JE, Hnisz D, Young RA. Transcriptional addiction in cancer. Cell. 2017;168(4):629\u201343. https:\/\/doi.org\/10.1016\/j.cell.2016.12.013.","journal-title":"Cell"},{"key":"798_CR225","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1146\/annurev-pharmtox-010716-105106","volume":"58","author":"RL Bennett","year":"2018","unstructured":"Bennett RL, Licht JD. Targeting epigenetics in cancer. Annu Rev Pharmacol Toxicol. 2018;58:187\u2013207. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010716-105106.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"4","key":"798_CR226","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.molcel.2015.10.042","volume":"60","author":"SF Cai","year":"2015","unstructured":"Cai SF, Chen CW, Armstrong SA. Drugging chromatin in cancer: recent advances and novel approaches. Mol Cell. 2015;60(4):561\u201370. https:\/\/doi.org\/10.1016\/j.molcel.2015.10.042.","journal-title":"Mol Cell"},{"issue":"1","key":"798_CR227","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41576-024-00760-8","volume":"26","author":"ZD Smith","year":"2025","unstructured":"Smith ZD, Hetzel S, Meissner A. DNA methylation in mammalian development and disease. Nat Rev Genet. 2025;26(1):7\u201330. https:\/\/doi.org\/10.1038\/s41576-024-00760-8.","journal-title":"Nat Rev Genet"},{"issue":"11","key":"798_CR228","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.tig.2021.05.002","volume":"37","author":"A Nishiyama","year":"2021","unstructured":"Nishiyama A, Nakanishi M. Navigating the DNA methylation landscape of cancer. Trends Genet. 2021;37(11):1012\u201327. https:\/\/doi.org\/10.1016\/j.tig.2021.05.002.","journal-title":"Trends Genet"},{"issue":"2","key":"798_CR229","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrg.2017.80","volume":"19","author":"F Lyko","year":"2018","unstructured":"Lyko F. The DNA methyltransferase family: a versatile toolkit for epigenetic regulation. Nat Rev Genet. 2018;19(2):81\u201392. https:\/\/doi.org\/10.1038\/nrg.2017.80.","journal-title":"Nat Rev Genet"},{"issue":"6","key":"798_CR230","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrm3589","volume":"14","author":"WA Pastor","year":"2013","unstructured":"Pastor WA, Aravind L, Rao A. TETonic shift: biological roles of TET proteins in DNA demethylation and transcription. Nat Rev Mol Cell Biol. 2013;14(6):341\u201356. https:\/\/doi.org\/10.1038\/nrm3589.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"12","key":"798_CR231","doi-asserted-by":"publisher","first-page":"3938","DOI":"10.1158\/1078-0432.Ccr-08-2783","volume":"15","author":"JP Issa","year":"2009","unstructured":"Issa JP, Kantarjian HM. Targeting DNA methylation. Clin Cancer Res. 2009;15(12):3938\u201346. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-08-2783.","journal-title":"Clin Cancer Res"},{"key":"798_CR232","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2024.108640","volume":"258","author":"AV Lee","year":"2024","unstructured":"Lee AV, Nestler KA, Chiappinelli KB. Therapeutic targeting of DNA methylation alterations in cancer. Pharmacol Ther. 2024;258:108640. https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108640.","journal-title":"Pharmacol Ther"},{"issue":"2","key":"798_CR233","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/sj.emboj.7600509","volume":"24","author":"C Brenner","year":"2005","unstructured":"Brenner C, Deplus R, Didelot C, Loriot A, Vir\u00e9 E, De Smet C, et al. Myc represses transcription through recruitment of DNA methyltransferase corepressor. Embo J. 2005;24(2):336\u201346. https:\/\/doi.org\/10.1038\/sj.emboj.7600509.","journal-title":"Embo J"},{"issue":"44","key":"798_CR234","doi-asserted-by":"publisher","first-page":"76898","DOI":"10.18632\/oncotarget.20176","volume":"8","author":"CJ Poole","year":"2017","unstructured":"Poole CJ, Zheng W, Lodh A, Yevtodiyenko A, Liefwalker D, Li H, et al. DNMT3B overexpression contributes to aberrant DNA methylation and MYC-driven tumor maintenance in T-ALL and Burkitt\u2019s lymphoma. Oncotarget. 2017;8(44):76898\u2013920. https:\/\/doi.org\/10.18632\/oncotarget.20176.","journal-title":"Oncotarget"},{"issue":"1","key":"798_CR235","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-025-03382-y","volume":"44","author":"C Muylaert","year":"2025","unstructured":"Muylaert C, Van Hemelrijck LA, Van der Vreken A, Heestermans R, Satilmis H, Verheye E, et al. The de novo DNA methyltransferase 3B is a novel epigenetic regulator of MYC in multiple myeloma, representing a promising therapeutic target to counter relapse. J Exp Clin Cancer Res. 2025;44(1):125. https:\/\/doi.org\/10.1186\/s13046-025-03382-y.","journal-title":"J Exp Clin Cancer Res"},{"issue":"18","key":"798_CR236","doi-asserted-by":"publisher","first-page":"4281","DOI":"10.1182\/blood-2008-10-183475","volume":"113","author":"A H\u00f6glund","year":"2009","unstructured":"H\u00f6glund A, Nilsson LM, Forshell LP, Maclean KH, Nilsson JA. Myc sensitizes p53-deficient cancer cells to the DNA-damaging effects of the DNA methyltransferase inhibitor decitabine. Blood. 2009;113(18):4281\u20138. https:\/\/doi.org\/10.1182\/blood-2008-10-183475.","journal-title":"Blood"},{"issue":"1","key":"798_CR237","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-14882-7","volume":"25","author":"Y Endo","year":"2025","unstructured":"Endo Y, Sugino RP, Takenobu H, Mukae K, Okada R, Shinno Y, et al. Synthetic lethality of EZH2 and DNMT inhibition suppresses neuroblastoma proliferation via MYCN destabilization. BMC Cancer. 2025;25(1):1759. https:\/\/doi.org\/10.1186\/s12885-025-14882-7.","journal-title":"BMC Cancer"},{"issue":"1","key":"798_CR238","doi-asserted-by":"publisher","DOI":"10.1186\/s13072-019-0278-5","volume":"12","author":"CJ Poole","year":"2019","unstructured":"Poole CJ, Lodh A, Choi JH, van Riggelen J. MYC deregulates TET1 and TET2 expression to control global DNA (hydroxy)methylation and gene expression to maintain a neoplastic phenotype in T-ALL. Epigenet Chromatin. 2019;12(1):41. https:\/\/doi.org\/10.1186\/s13072-019-0278-5.","journal-title":"Epigenet Chromatin"},{"issue":"1","key":"798_CR239","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01513-6","volume":"16","author":"L Chen","year":"2023","unstructured":"Chen L, Ren A, Zhao Y, Chen H, Wu Q, Zheng M, et al. Direct inhibition of dioxygenases TET1 by the rheumatoid arthritis drug auranofin selectively induces cancer cell death in T-ALL. J Hematol Oncol. 2023;16(1):113. https:\/\/doi.org\/10.1186\/s13045-023-01513-6.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"798_CR240","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/j.celrep.2014.04.040","volume":"7","author":"CJ Mariani","year":"2014","unstructured":"Mariani CJ, Vasanthakumar A, Madzo J, Yesilkanal A, Bhagat T, Yu Y, et al. TET1-mediated hydroxymethylation facilitates hypoxic gene induction in neuroblastoma. Cell Rep. 2014;7(5):1343\u201352. https:\/\/doi.org\/10.1016\/j.celrep.2014.04.040.","journal-title":"Cell Rep"},{"issue":"1","key":"798_CR241","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/s41698-025-01090-6","volume":"9","author":"A Ma\u00f1as","year":"2025","unstructured":"Ma\u00f1as A, Seger A, Adamska A, Smyrilli K, Siaw JT, Radke K, et al. Targeted ferroptosis induction enhances chemotherapy efficacy in chemoresistant neuroblastoma. NPJ Precis Oncol. 2025;9(1):311. https:\/\/doi.org\/10.1038\/s41698-025-01090-6.","journal-title":"NPJ Precis Oncol."},{"issue":"4","key":"798_CR242","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.semcancer.2006.08.001","volume":"16","author":"VH Cowling","year":"2006","unstructured":"Cowling VH, Cole MD. Mechanism of transcriptional activation by the Myc oncoproteins. Semin Cancer Biol. 2006;16(4):242\u201352. https:\/\/doi.org\/10.1016\/j.semcancer.2006.08.001.","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"798_CR243","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1093\/bfgp\/ell032","volume":"5","author":"H Fukuda","year":"2006","unstructured":"Fukuda H, Sano N, Muto S, Horikoshi M. Simple histone acetylation plays a complex role in the regulation of gene expression. Brief Funct Genom Proteomics. 2006;5(3):190\u2013208. https:\/\/doi.org\/10.1093\/bfgp\/ell032.","journal-title":"Brief Funct Genom Proteomics"},{"issue":"6","key":"798_CR244","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/bjc.2016.36","volume":"114","author":"E Ceccacci","year":"2016","unstructured":"Ceccacci E, Minucci S. Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia. Br J Cancer. 2016;114(6):605\u201311. https:\/\/doi.org\/10.1038\/bjc.2016.36.","journal-title":"Br J Cancer"},{"issue":"1","key":"798_CR245","doi-asserted-by":"publisher","first-page":"14","DOI":"10.4161\/epi.1.1.2644","volume":"1","author":"TY Kim","year":"2006","unstructured":"Kim TY, Bang YJ, Robertson KD. Histone deacetylase inhibitors for cancer therapy. Epigenetics. 2006;1(1):14\u201323. https:\/\/doi.org\/10.4161\/epi.1.1.2644.","journal-title":"Epigenetics"},{"key":"798_CR246","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.560487","volume":"10","author":"D Wu","year":"2020","unstructured":"Wu D, Qiu Y, Jiao Y, Qiu Z, Liu D. Small molecules targeting HATs, HDACs, and BRDs in cancer therapy. Front Oncol. 2020;10:560487. https:\/\/doi.org\/10.3389\/fonc.2020.560487.","journal-title":"Front Oncol"},{"issue":"7","key":"798_CR247","doi-asserted-by":"publisher","first-page":"714","DOI":"10.2174\/1568026615666150825125857","volume":"16","author":"E Kim","year":"2016","unstructured":"Kim E, Bisson WH, L\u00f6hr CV, Williams DE, Ho E, Dashwood RH, et al. Histone and non-histone targets of dietary deacetylase inhibitors. Curr Top Med Chem. 2016;16(7):714\u201331. https:\/\/doi.org\/10.2174\/1568026615666150825125857.","journal-title":"Curr Top Med Chem"},{"issue":"6","key":"798_CR248","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/sj.embor.embor861","volume":"4","author":"SR Frank","year":"2003","unstructured":"Frank SR, Parisi T, Taubert S, Fernandez P, Fuchs M, Chan HM, et al. MYC recruits the TIP60 histone acetyltransferase complex to chromatin. EMBO Rep. 2003;4(6):575\u201380. https:\/\/doi.org\/10.1038\/sj.embor.embor861.","journal-title":"EMBO Rep"},{"issue":"16","key":"798_CR249","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1101\/gad.906601","volume":"15","author":"SR Frank","year":"2001","unstructured":"Frank SR, Schroeder M, Fernandez P, Taubert S, Amati B. Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. Genes Dev. 2001;15(16):2069\u201382. https:\/\/doi.org\/10.1101\/gad.906601.","journal-title":"Genes Dev"},{"issue":"5","key":"798_CR250","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/sj.embor.embor821","volume":"4","author":"J Vervoorts","year":"2003","unstructured":"Vervoorts J, L\u00fcscher-Firzlaff JM, Rottmann S, Lilischkis R, Walsemann G, Dohmann K, et al. Stimulation of c-MYC transcriptional activity and acetylation by recruitment of the cofactor CBP. EMBO Rep. 2003;4(5):484\u201390. https:\/\/doi.org\/10.1038\/sj.embor.embor821.","journal-title":"EMBO Rep"},{"issue":"1","key":"798_CR251","doi-asserted-by":"publisher","first-page":"5823","DOI":"10.1038\/s41467-020-19452-y","volume":"11","author":"K Helmsauer","year":"2020","unstructured":"Helmsauer K, Valieva ME, Ali S, Chamorro Gonz\u00e1lez R, Sch\u00f6pflin R, R\u00f6efzaad C, et al. Enhancer hijacking determines extrachromosomal circular MYCN amplicon architecture in neuroblastoma. Nat Commun. 2020;11(1):5823. https:\/\/doi.org\/10.1038\/s41467-020-19452-y.","journal-title":"Nat Commun"},{"issue":"3","key":"798_CR252","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1158\/2159-8290.Cd-17-0993","volume":"8","author":"MW Zimmerman","year":"2018","unstructured":"Zimmerman MW, Liu Y, He S, Durbin AD, Abraham BJ, Easton J, et al. MYC drives a subset of high-risk pediatric neuroblastomas and is activated through mechanisms including enhancer hijacking and focal enhancer amplification. Cancer Discov. 2018;8(3):320\u201335. https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-0993.","journal-title":"Cancer Discov"},{"issue":"2","key":"798_CR253","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.celrep.2018.03.056","volume":"23","author":"J Schuijers","year":"2018","unstructured":"Schuijers J, Manteiga JC, Weintraub AS, Day DS, Zamudio AV, Hnisz D, et al. Transcriptional dysregulation of MYC reveals common enhancer-docking mechanism. Cell Rep. 2018;23(2):349\u201360. https:\/\/doi.org\/10.1016\/j.celrep.2018.03.056.","journal-title":"Cell Rep"},{"issue":"2","key":"798_CR254","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1093\/neuonc\/noaa191","volume":"23","author":"J Ecker","year":"2021","unstructured":"Ecker J, Thatikonda V, Sigismondo G, Selt F, Valinciute G, Oehme I, et al. Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma. Neuro Oncol. 2021;23(2):226\u201339. https:\/\/doi.org\/10.1093\/neuonc\/noaa191.","journal-title":"Neuro Oncol"},{"issue":"32","key":"798_CR255","doi-asserted-by":"publisher","first-page":"22221","DOI":"10.1074\/jbc.M113.538744","volume":"289","author":"P Garcia-Sanz","year":"2014","unstructured":"Garcia-Sanz P, Quintanilla A, Lafita MC, Moreno-Bueno G, Garc\u00eda-Gutierrez L, Tabor V, et al. Sin3b interacts with Myc and decreases Myc levels*. J Biol Chem. 2014;289(32):22221\u201336. https:\/\/doi.org\/10.1074\/jbc.M113.538744.","journal-title":"J Biol Chem"},{"issue":"10","key":"798_CR256","doi-asserted-by":"publisher","first-page":"3624","DOI":"10.1158\/0008-5472.Can-07-6552","volume":"68","author":"JF Kurland","year":"2008","unstructured":"Kurland JF, Tansey WP. Myc-mediated transcriptional repression by recruitment of histone deacetylase. Cancer Res. 2008;68(10):3624\u20139. https:\/\/doi.org\/10.1158\/0008-5472.Can-07-6552.","journal-title":"Cancer Res"},{"issue":"9","key":"798_CR257","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.4161\/cbt.29500","volume":"15","author":"J Wang","year":"2014","unstructured":"Wang J, Elahi A, Ajidahun A, Clark W, Hernandez J, Achille A, et al. The interplay between histone deacetylases and c-Myc in the transcriptional suppression of HPP1 in colon cancer. Cancer Biol Ther. 2014;15(9):1198\u2013207. https:\/\/doi.org\/10.4161\/cbt.29500.","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"798_CR258","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13073-018-0597-3","volume":"10","author":"M Tanioka","year":"2018","unstructured":"Tanioka M, Mott KR, Hollern DP, Fan C, Darr DB, Perou CM. Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer. Genome Med. 2018;10(1):86. https:\/\/doi.org\/10.1186\/s13073-018-0597-3.","journal-title":"Genome Med"},{"issue":"2","key":"798_CR259","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1093\/neuonc\/noaa191","volume":"23","author":"J Ecker","year":"2020","unstructured":"Ecker J, Thatikonda V, Sigismondo G, Selt F, Valinciute G, Oehme I, et al. Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma. Neurooncology. 2020;23(2):226\u201339. https:\/\/doi.org\/10.1093\/neuonc\/noaa191.","journal-title":"Neurooncology"},{"issue":"1","key":"798_CR260","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s11060-023-04319-1","volume":"163","author":"G Valinciute","year":"2023","unstructured":"Valinciute G, Ecker J, Selt F, Hielscher T, Sigaud R, Ridinger J, et al. Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells. J Neurooncol. 2023;163(1):143\u201358. https:\/\/doi.org\/10.1007\/s11060-023-04319-1.","journal-title":"J Neurooncol"},{"key":"798_CR261","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910671","author":"M Cassandri","year":"2021","unstructured":"Cassandri M, Pomella S, Rossetti A, Petragnano F, Milazzo L, Vulcano F, et al. MS-275 (Entinostat) promotes radio-sensitivity in PAX3-FOXO1 rhabdomyosarcoma cells. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms221910671.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"798_CR262","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3126-7","volume":"17","author":"R Bayat Mokhtari","year":"2017","unstructured":"Bayat Mokhtari R, Baluch N, Ka Hon Tsui M, Kumar S, S. Homayouni T, Aitken K, et al. Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma. BMC Cancer. 2017;17(1):156. https:\/\/doi.org\/10.1186\/s12885-017-3126-7.","journal-title":"BMC Cancer"},{"issue":"Supplement_2","key":"798_CR263","doi-asserted-by":"publisher","first-page":"ii107","DOI":"10.1093\/neuonc\/noz036.179","volume":"21","author":"V Marquardt","year":"2019","unstructured":"Marquardt V, Theruvath J, Pauck D, Picard D, Qin N, Bl\u00fcmel L, et al. MEDU-20. HDAC and NF\u03baB antagonists synergistically inhibit growth of MYC-driven medulloblastoma. Neuro Oncol. 2019;21(Supplement_2):ii107. https:\/\/doi.org\/10.1093\/neuonc\/noz036.179.","journal-title":"Neuro Oncol"},{"issue":"19","key":"798_CR264","doi-asserted-by":"publisher","first-page":"8071","DOI":"10.1073\/pnas.0702294104","volume":"104","author":"RK Lindemann","year":"2007","unstructured":"Lindemann RK, Newbold A, Whitecross KF, Cluse LA, Frew AJ, Ellis L, et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci USA. 2007;104(19):8071\u20136. https:\/\/doi.org\/10.1073\/pnas.0702294104.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"798_CR265","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1158\/0008-5472.Can-10-2259","volume":"71","author":"L Kretzner","year":"2011","unstructured":"Kretzner L, Scuto A, Dino PM, Kowolik CM, Wu J, Ventura P, et al. Combining histone deacetylase inhibitor vorinostat with Aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA Levels. Cancer Res. 2011;71(11):3912\u201320. https:\/\/doi.org\/10.1158\/0008-5472.Can-10-2259.","journal-title":"Cancer Res"},{"issue":"7674","key":"798_CR266","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nature24028","volume":"550","author":"LM Lasko","year":"2017","unstructured":"Lasko LM, Jakob CG, Edalji RP, Qiu W, Montgomery D, Digiammarino EL, et al. Discovery of a selective catalytic p300\/CBP inhibitor that targets lineage-specific tumours. Nature. 2017;550(7674):128\u201332. https:\/\/doi.org\/10.1038\/nature24028.","journal-title":"Nature"},{"issue":"5","key":"798_CR267","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1158\/2159-8290.Cd-20-0751","volume":"11","author":"J Welti","year":"2021","unstructured":"Welti J, Sharp A, Brooks N, Yuan W, McNair C, Chand SN, et al. Targeting the p300\/CBP axis in lethal prostate cancer. Cancer Discov. 2021;11(5):1118\u201337. https:\/\/doi.org\/10.1158\/2159-8290.Cd-20-0751.","journal-title":"Cancer Discov"},{"issue":"28","key":"798_CR268","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1038\/s41388-025-03417-w","volume":"44","author":"J Liu","year":"2025","unstructured":"Liu J, Wang X, He D, Maasoumyhaghighi H, Nouri M, Wu M, et al. Therapeutic targeting of the p300\/CBP bromodomain enhances the efficacy of immune checkpoint blockade therapy. Oncogene. 2025;44(28):2386\u201395. https:\/\/doi.org\/10.1038\/s41388-025-03417-w.","journal-title":"Oncogene"},{"issue":"1","key":"798_CR269","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1038\/s41467-024-47102-0","volume":"15","author":"NAM Shendy","year":"2024","unstructured":"Shendy NAM, Bikowitz M, Sigua LH, Zhang Y, Mercier A, Khashana Y, et al. Group 3 medulloblastoma transcriptional networks collapse under domain specific EP300\/CBP inhibition. Nat Commun. 2024;15(1):3483. https:\/\/doi.org\/10.1038\/s41467-024-47102-0.","journal-title":"Nat Commun"},{"issue":"7717","key":"798_CR270","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s41586-018-0387-5","volume":"560","author":"JB Baell","year":"2018","unstructured":"Baell JB, Leaver DJ, Hermans SJ, Kelly GL, Brennan MS, Downer NL, et al. Inhibitors of histone acetyltransferases KAT6A\/B induce senescence and arrest tumour growth. Nature. 2018;560(7717):253\u20137. https:\/\/doi.org\/10.1038\/s41586-018-0387-5.","journal-title":"Nature"},{"issue":"10","key":"798_CR271","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.chembiol.2023.07.005","volume":"30","author":"S Sharma","year":"2023","unstructured":"Sharma S, Chung CY, Uryu S, Petrovic J, Cao J, Rickard A, et al. Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A\/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer. Cell Chem Biol. 2023;30(10):1191-210.e20. https:\/\/doi.org\/10.1016\/j.chembiol.2023.07.005.","journal-title":"Cell Chem Biol"},{"issue":"8","key":"798_CR272","first-page":"1830","volume":"9","author":"LM Mustachio","year":"2019","unstructured":"Mustachio LM, Roszik J, Farria AT, Guerra K, Dent SY. Repression of GCN5 expression or activity attenuates c-MYC expression in non-small cell lung cancer. Am J Cancer Res. 2019;9(8):1830\u201345.","journal-title":"Am J Cancer Res"},{"key":"798_CR273","doi-asserted-by":"publisher","DOI":"10.3390\/epigenomes6030028","author":"B German","year":"2022","unstructured":"German B, Ellis L. Polycomb directed cell fate decisions in development and cancer. Epigenomes. 2022. https:\/\/doi.org\/10.3390\/epigenomes6030028.","journal-title":"Epigenomes"},{"issue":"9","key":"798_CR274","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1111\/febs.13083","volume":"282","author":"P Viz\u00e1n","year":"2015","unstructured":"Viz\u00e1n P, Beringer M, Ballar\u00e9 C, Di Croce L. Role of PRC2-associated factors in stem cells and disease. FEBS J. 2015;282(9):1723\u201335. https:\/\/doi.org\/10.1111\/febs.13083.","journal-title":"FEBS J"},{"issue":"24","key":"798_CR275","doi-asserted-by":"publisher","first-page":"5449","DOI":"10.1158\/0008-5472.Can-20-2147","volume":"80","author":"ML Eich","year":"2020","unstructured":"Eich ML, Athar M, Ferguson JE 3rd, Varambally S. EZH2-targeted therapies in cancer: hype or a reality. Cancer Res. 2020;80(24):5449\u201358. https:\/\/doi.org\/10.1158\/0008-5472.Can-20-2147.","journal-title":"Cancer Res"},{"issue":"1","key":"798_CR276","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00937-8","volume":"13","author":"R Duan","year":"2020","unstructured":"Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. J Hematol Oncol. 2020;13(1):104. https:\/\/doi.org\/10.1186\/s13045-020-00937-8.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"798_CR277","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm.4036","volume":"22","author":"KH Kim","year":"2016","unstructured":"Kim KH, Roberts CW. Targeting EZH2 in cancer. Nat Med. 2016;22(2):128\u201334. https:\/\/doi.org\/10.1038\/nm.4036.","journal-title":"Nat Med"},{"issue":"16","key":"798_CR278","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.2217\/epi-2020-0186","volume":"12","author":"N Kang","year":"2020","unstructured":"Kang N, Eccleston M, Clermont PL, Latarani M, Male DK, Wang Y, et al. EZH2 inhibition: a promising strategy to prevent cancer immune editing. Epigenomics. 2020;12(16):1457\u201376. https:\/\/doi.org\/10.2217\/epi-2020-0186.","journal-title":"Epigenomics"},{"issue":"6","key":"798_CR279","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-023-02025-6","volume":"40","author":"Y Liu","year":"2023","unstructured":"Liu Y, Yang Q. The roles of EZH2 in cancer and its inhibitors. Med Oncol. 2023;40(6):167. https:\/\/doi.org\/10.1007\/s12032-023-02025-6.","journal-title":"Med Oncol"},{"issue":"3","key":"798_CR280","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/d41573-020-00024-0","volume":"19","author":"A Mullard","year":"2020","unstructured":"Mullard A. FDA approves an inhibitor of a novel \u201cepigenetic writer.\u201d Nat Rev Drug Discov. 2020;19(3):156. https:\/\/doi.org\/10.1038\/d41573-020-00024-0.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"798_CR281","doi-asserted-by":"publisher","first-page":"158","DOI":"10.6004\/jadpro.2022.13.2.7","volume":"13","author":"R Straining","year":"2022","unstructured":"Straining R, Eighmy W. Tazemetostat: EZH2 Inhibitor. J Adv Pract Oncol. 2022;13(2):158\u201363. https:\/\/doi.org\/10.6004\/jadpro.2022.13.2.7.","journal-title":"J Adv Pract Oncol"},{"issue":"9","key":"798_CR282","doi-asserted-by":"publisher","first-page":"669","DOI":"10.18632\/oncotarget.327","volume":"2","author":"CM Koh","year":"2011","unstructured":"Koh CM, Iwata T, Zheng Q, Bethel C, Yegnasubramanian S, De Marzo AM. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget. 2011;2(9):669\u201383.","journal-title":"Oncotarget"},{"issue":"5","key":"798_CR283","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1158\/1535-7163.Mct-15-0750","volume":"15","author":"X Wu","year":"2016","unstructured":"Wu X, Liu D, Tao D, Xiang W, Xiao X, Wang M, et al. BRD4 regulates EZH2 transcription through upregulation of C-MYC and represents a novel therapeutic target in bladder cancer. Mol Cancer Ther. 2016;15(5):1029\u201342. https:\/\/doi.org\/10.1158\/1535-7163.Mct-15-0750.","journal-title":"Mol Cancer Ther"},{"issue":"23","key":"798_CR284","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1182\/blood.2022016428","volume":"140","author":"M Vanden Bempt","year":"2022","unstructured":"Vanden Bempt M, Debackere K, Demeyer S, Van Thillo Q, Meeuws N, Prieto C, et al. Aberrant MYCN expression drives oncogenic hijacking of EZH2 as a transcriptional activator in peripheral T-cell lymphoma. Blood. 2022;140(23):2463\u201376. https:\/\/doi.org\/10.1182\/blood.2022016428.","journal-title":"Blood"},{"issue":"10","key":"798_CR285","doi-asserted-by":"publisher","first-page":"e3126","DOI":"10.1038\/cddis.2017.526","volume":"8","author":"L Liu","year":"2017","unstructured":"Liu L, Xu F, Chang CK, He Q, Wu LY, Zhang Z, et al. MYCN contributes to the malignant characteristics of erythroleukemia through EZH2-mediated epigenetic repression of p21. Cell Death Dis. 2017;8(10):e3126. https:\/\/doi.org\/10.1038\/cddis.2017.526.","journal-title":"Cell Death Dis"},{"issue":"1","key":"798_CR286","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1172\/JCI90793","volume":"128","author":"L Chen","year":"2018","unstructured":"Chen L, Alexe G, Dharia NV, Ross L, Iniguez AB, Conway AS, et al. CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. J Clin Investig. 2018;128(1):446\u201362. https:\/\/doi.org\/10.1172\/JCI90793.","journal-title":"J Clin Investig"},{"issue":"12","key":"798_CR287","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1038\/leu.2013.94","volume":"27","author":"X Zhao","year":"2013","unstructured":"Zhao X, Lwin T, Zhang X, Huang A, Wang J, Marquez VE, et al. Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity. Leukemia. 2013;27(12):2341\u201350. https:\/\/doi.org\/10.1038\/leu.2013.94.","journal-title":"Leukemia"},{"issue":"9","key":"798_CR288","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/modpathol.2016.114","volume":"29","author":"X Tian","year":"2016","unstructured":"Tian X, Pelton A, Shahsafaei A, Dorfman DM. Differential expression of enhancer of zeste homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1\/2 and MYC in aggressive B-cell lymphomas. Mod Pathol. 2016;29(9):1050\u20137. https:\/\/doi.org\/10.1038\/modpathol.2016.114.","journal-title":"Mod Pathol"},{"issue":"13","key":"798_CR289","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41388-023-02618-5","volume":"42","author":"X Yu","year":"2023","unstructured":"Yu X, Wang J, Gong W, Ma A, Shen Y, Zhang C, et al. Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader. Oncogene. 2023;42(13):994\u20131009. https:\/\/doi.org\/10.1038\/s41388-023-02618-5.","journal-title":"Oncogene"},{"issue":"12","key":"798_CR290","doi-asserted-by":"publisher","first-page":"8332","DOI":"10.1074\/jbc.M113.454280","volume":"288","author":"D Corvetta","year":"2013","unstructured":"Corvetta D, Chayka O, Gherardi S, D\u2019Acunto CW, Cantilena S, Valli E, et al. Physical interaction between MYCN oncogene and polycomb repressive complex 2 (PRC2) in neuroblastoma: functional and therapeutic implications. J Biol Chem. 2013;288(12):8332\u201341. https:\/\/doi.org\/10.1074\/jbc.M113.454280.","journal-title":"J Biol Chem"},{"issue":"1","key":"798_CR291","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27609-6","volume":"13","author":"L Wang","year":"2022","unstructured":"Wang L, Chen C, Song Z, Wang H, Ye M, Wang D, et al. EZH2 depletion potentiates MYC degradation inhibiting neuroblastoma and small cell carcinoma tumor formation. Nat Commun. 2022;13(1):12. https:\/\/doi.org\/10.1038\/s41467-021-27609-6.","journal-title":"Nat Commun"},{"issue":"4","key":"798_CR292","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ccell.2016.09.005","volume":"30","author":"E Dardenne","year":"2016","unstructured":"Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L, et al. N-Myc Induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer. Cancer Cell. 2016;30(4):563\u201377. https:\/\/doi.org\/10.1016\/j.ccell.2016.09.005.","journal-title":"Cancer Cell"},{"key":"798_CR293","doi-asserted-by":"publisher","DOI":"10.14800\/rd.1529","author":"M Alzrigat","year":"2017","unstructured":"Alzrigat M, Jernberg-Wiklund H. The miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myeloma. RNA Dis. 2017. https:\/\/doi.org\/10.14800\/rd.1529.","journal-title":"RNA Dis."},{"issue":"6","key":"798_CR294","doi-asserted-by":"publisher","first-page":"10213","DOI":"10.18632\/oncotarget.14378","volume":"8","author":"M Alzrigat","year":"2017","unstructured":"Alzrigat M, Parraga AA, Agarwal P, Zureigat H, Osterborg A, Nahi H, et al. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions. Oncotarget. 2017;8(6):10213\u201324. https:\/\/doi.org\/10.18632\/oncotarget.14378.","journal-title":"Oncotarget"},{"issue":"10","key":"798_CR295","doi-asserted-by":"publisher","first-page":"4202","DOI":"10.1182\/blood-2008-03-147645","volume":"112","author":"S Sander","year":"2008","unstructured":"Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler HA, Barth TF, et al. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood. 2008;112(10):4202\u201312. https:\/\/doi.org\/10.1182\/blood-2008-03-147645.","journal-title":"Blood"},{"issue":"4","key":"798_CR296","doi-asserted-by":"publisher","first-page":"634","DOI":"10.4161\/epi.27957","volume":"9","author":"G Kuser-Abali","year":"2014","unstructured":"Kuser-Abali G, Alptekin A, Cinar B. Overexpression of MYC and EZH2 cooperates to epigenetically silence MST1 expression. Epigenetics. 2014;9(4):634\u201343. https:\/\/doi.org\/10.4161\/epi.27957.","journal-title":"Epigenetics"},{"key":"798_CR297","doi-asserted-by":"publisher","DOI":"10.3892\/or.2023.8556","author":"K Shishido","year":"2023","unstructured":"Shishido K, Purvis IJ, Velpula KK, Venkataraman S, Vibhakar R, Asuthkar S. Targeting B7\u2013H3 through EZH2 inhibition in MYC-positive group 3 medulloblastoma. Oncol Rep. 2023. https:\/\/doi.org\/10.3892\/or.2023.8556.","journal-title":"Oncol Rep"},{"issue":"3","key":"798_CR298","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/s41556-022-00850-x","volume":"24","author":"J Wang","year":"2022","unstructured":"Wang J, Yu X, Gong W, Liu X, Park KS, Ma A, et al. EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis. Nat Cell Biol. 2022;24(3):384\u201399. https:\/\/doi.org\/10.1038\/s41556-022-00850-x.","journal-title":"Nat Cell Biol"},{"issue":"14","key":"798_CR299","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1101\/gad.989402","volume":"16","author":"M Tachibana","year":"2002","unstructured":"Tachibana M, Sugimoto K, Nozaki M, Ueda J, Ohta T, Ohki M, et al. G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. Genes Dev. 2002;16(14):1779\u201391. https:\/\/doi.org\/10.1101\/gad.989402.","journal-title":"Genes Dev"},{"issue":"27","key":"798_CR300","doi-asserted-by":"publisher","first-page":"25309","DOI":"10.1074\/jbc.M101914200","volume":"276","author":"M Tachibana","year":"2001","unstructured":"Tachibana M, Sugimoto K, Fukushima T, Shinkai Y. Set domain-containing protein, G9a, is a novel lysine-preferring mammalian histone methyltransferase with hyperactivity and specific selectivity to lysines 9 and 27 of histone H3. J Biol Chem. 2001;276(27):25309\u201317. https:\/\/doi.org\/10.1074\/jbc.M101914200.","journal-title":"J Biol Chem"},{"issue":"2","key":"798_CR301","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.molcel.2013.12.005","volume":"53","author":"C Mozzetta","year":"2014","unstructured":"Mozzetta C, Pontis J, Fritsch L, Robin P, Portoso M, Proux C, et al. The histone H3 lysine 9 methyltransferases G9a and GLP regulate polycomb repressive complex 2-mediated gene silencing. Mol Cell. 2014;53(2):277\u201389. https:\/\/doi.org\/10.1016\/j.molcel.2013.12.005.","journal-title":"Mol Cell"},{"issue":"11","key":"798_CR302","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41389-021-00370-7","volume":"10","author":"JR Haebe","year":"2021","unstructured":"Haebe JR, Bergin CJ, Sandouka T, Benoit YD. Emerging role of G9a in cancer stemness and promises as a therapeutic target. Oncogenesis. 2021;10(11):76. https:\/\/doi.org\/10.1038\/s41389-021-00370-7.","journal-title":"Oncogenesis"},{"key":"798_CR303","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3389\/fimmu.2015.00487","volume":"6","author":"F Casciello","year":"2015","unstructured":"Casciello F, Windloch K, Gannon F, Lee JS. Functional role of G9a histone methyltransferase in cancer. Front Immunol. 2015;6:487. https:\/\/doi.org\/10.3389\/fimmu.2015.00487.","journal-title":"Front Immunol"},{"key":"798_CR304","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2025.149681","volume":"968","author":"F Moreira-Silva","year":"2025","unstructured":"Moreira-Silva F, Macedo-Silva C, Jer\u00f3nimo C, Julio MK. Translating G9a epigenetics\u2019 role: from cell machinery to cancer therapy. Gene. 2025;968:149681. https:\/\/doi.org\/10.1016\/j.gene.2025.149681.","journal-title":"Gene"},{"issue":"4","key":"798_CR305","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ccell.2018.09.001","volume":"34","author":"WB Tu","year":"2018","unstructured":"Tu WB, Shiah YJ, Lourenco C, Mullen PJ, Dingar D, Redel C, et al. MYC interacts with the G9a histone methyltransferase to drive transcriptional repression and tumorigenesis. Cancer Cell. 2018;34(4):579-95.e8. https:\/\/doi.org\/10.1016\/j.ccell.2018.09.001.","journal-title":"Cancer Cell"},{"issue":"11","key":"798_CR306","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1002\/1878-0261.13417","volume":"17","author":"DKH Thng","year":"2023","unstructured":"Thng DKH, Hooi L, Toh CCM, Lim JJ, Rajagopalan D, Syariff IQC, et al. Histone-lysine N-methyltransferase EHMT2 (G9a) inhibition mitigates tumorigenicity in Myc-driven liver cancer. Mol Oncol. 2023;17(11):2275\u201394. https:\/\/doi.org\/10.1002\/1878-0261.13417.","journal-title":"Mol Oncol"},{"issue":"4","key":"798_CR307","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1084\/jem.20111512","volume":"209","author":"D Horiuchi","year":"2012","unstructured":"Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez-Angulo AM, et al. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med. 2012;209(4):679\u201396. https:\/\/doi.org\/10.1084\/jem.20111512.","journal-title":"J Exp Med"},{"issue":"17","key":"798_CR308","doi-asserted-by":"publisher","first-page":"28101","DOI":"10.18632\/oncotarget.15891","volume":"8","author":"N Gupta","year":"2017","unstructured":"Gupta N, Jung K, Wu C, Alshareef A, Alqahtani H, Damaraju S, et al. High Myc expression and transcription activity underlies intra-tumoral heterogeneity in triple-negative breast cancer. Oncotarget. 2017;8(17):28101\u201315. https:\/\/doi.org\/10.18632\/oncotarget.15891.","journal-title":"Oncotarget"},{"issue":"2","key":"798_CR309","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.3892\/mmr.2017.8190","volume":"17","author":"XR Liu","year":"2018","unstructured":"Liu XR, Zhou LH, Hu JX, Liu LM, Wan HP, Zhang XQ. UNC0638, a G9a inhibitor, suppresses epithelial-mesenchymal transition-mediated cellular migration and invasion in triple negative breast cancer. Mol Med Rep. 2018;17(2):2239\u201344. https:\/\/doi.org\/10.3892\/mmr.2017.8190.","journal-title":"Mol Med Rep"},{"issue":"2","key":"798_CR310","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.113714","volume":"43","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, Shi Y, Liu S, Yang W, Chen H, Guo N, et al. EZH2\/G9a interact to mediate drug resistance in non-small-cell lung cancer by regulating the SMAD4\/ERK\/c-Myc signaling axis. Cell Rep. 2024;43(2):113714. https:\/\/doi.org\/10.1016\/j.celrep.2024.113714.","journal-title":"Cell Rep"},{"key":"798_CR311","doi-asserted-by":"publisher","first-page":"818","DOI":"10.3389\/fonc.2020.00818","volume":"10","author":"J Bellamy","year":"2020","unstructured":"Bellamy J, Szemes M, Melegh Z, Dallosso A, Kollareddy M, Catchpoole D, et al. Increased efficacy of histone methyltransferase G9a inhibitors against MYCN-amplified neuroblastoma. Front Oncol. 2020;10:818. https:\/\/doi.org\/10.3389\/fonc.2020.00818.","journal-title":"Front Oncol"},{"issue":"9","key":"798_CR312","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/bloodadvances.2020003217","volume":"5","author":"E De Smedt","year":"2021","unstructured":"De Smedt E, Devin J, Muylaert C, Robert N, Requirand G, Vlummens P, et al. G9a\/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor-mediated cell death. Blood Adv. 2021;5(9):2325\u201338. https:\/\/doi.org\/10.1182\/bloodadvances.2020003217.","journal-title":"Blood Adv"},{"key":"798_CR313","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.593964","volume":"8","author":"XX Ke","year":"2020","unstructured":"Ke XX, Zhang R, Zhong X, Zhang L, Cui H. Deficiency of G9a inhibits cell proliferation and activates autophagy via transcriptionally regulating c-Myc expression in glioblastoma. Front Cell Dev Biol. 2020;8:593964. https:\/\/doi.org\/10.3389\/fcell.2020.593964.","journal-title":"Front Cell Dev Biol"},{"key":"798_CR314","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biocel.2019.03.010","volume":"111","author":"EL Eskelinen","year":"2019","unstructured":"Eskelinen EL. Autophagy: supporting cellular and organismal homeostasis by self-eating. Int J Biochem Cell Biol. 2019;111:1\u201310. https:\/\/doi.org\/10.1016\/j.biocel.2019.03.010.","journal-title":"Int J Biochem Cell Biol"},{"issue":"12","key":"798_CR315","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1038\/nrc2254","volume":"7","author":"R Mathew","year":"2007","unstructured":"Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. Nat Rev Cancer. 2007;7(12):961\u20137. https:\/\/doi.org\/10.1038\/nrc2254.","journal-title":"Nat Rev Cancer"},{"issue":"17","key":"798_CR316","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1101\/gad.287524.116","volume":"30","author":"R Amaravadi","year":"2016","unstructured":"Amaravadi R, Kimmelman AC, White E. Recent insights into the function of autophagy in cancer. Genes Dev. 2016;30(17):1913\u201330. https:\/\/doi.org\/10.1101\/gad.287524.116.","journal-title":"Genes Dev"},{"issue":"7010","key":"798_CR317","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/nature02985","volume":"431","author":"H Wang","year":"2004","unstructured":"Wang H, Wang L, Erdjument-Bromage H, Vidal M, Tempst P, Jones RS, et al. Role of histone H2A ubiquitination in polycomb silencing. Nature. 2004;431(7010):873\u20138. https:\/\/doi.org\/10.1038\/nature02985.","journal-title":"Nature"},{"issue":"1","key":"798_CR318","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19722-9","volume":"11","author":"H Barbour","year":"2020","unstructured":"Barbour H, Daou S, Hendzel M, Affar EB. Polycomb group-mediated histone H2A monoubiquitination in epigenome regulation and nuclear processes. Nat Commun. 2020;11(1):5947. https:\/\/doi.org\/10.1038\/s41467-020-19722-9.","journal-title":"Nat Commun"},{"issue":"5","key":"798_CR319","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/0092-8674(91)90383-a","volume":"65","author":"Y Haupt","year":"1991","unstructured":"Haupt Y, Alexander WS, Barri G, Klinken SP, Adams JM. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice. Cell. 1991;65(5):753\u201363. https:\/\/doi.org\/10.1016\/0092-8674(91)90383-a.","journal-title":"Cell"},{"issue":"11","key":"798_CR320","first-page":"3161","volume":"8","author":"Y Haupt","year":"1993","unstructured":"Haupt Y, Bath ML, Harris AW, Adams JM. bmi-1 transgene induces lymphomas and collaborates with myc in tumorigenesis. Oncogene. 1993;8(11):3161\u20134.","journal-title":"Oncogene"},{"issue":"20","key":"798_CR321","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1101\/gad.13.20.2678","volume":"13","author":"JJ Jacobs","year":"1999","unstructured":"Jacobs JJ, Scheijen B, Voncken JW, Kieboom K, Berns A, van Lohuizen M. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a\/ARF. Genes Dev. 1999;13(20):2678\u201390. https:\/\/doi.org\/10.1101\/gad.13.20.2678.","journal-title":"Genes Dev"},{"issue":"13","key":"798_CR322","doi-asserted-by":"publisher","first-page":"5528","DOI":"10.1158\/0008-5472.Can-09-4229","volume":"70","author":"Z Jagani","year":"2010","unstructured":"Jagani Z, Wiederschain D, Loo A, He D, Mosher R, Fordjour P, et al. The polycomb group protein Bmi-1 is essential for the growth of multiple myeloma cells. Cancer Res. 2010;70(13):5528\u201338. https:\/\/doi.org\/10.1158\/0008-5472.Can-09-4229.","journal-title":"Cancer Res"},{"issue":"45","key":"798_CR323","doi-asserted-by":"publisher","first-page":"34696","DOI":"10.1074\/jbc.M604009200","volume":"281","author":"H Cui","year":"2006","unstructured":"Cui H, Ma J, Ding J, Li T, Alam G, Ding HF. Bmi-1 regulates the differentiation and clonogenic self-renewal of I-type neuroblastoma cells in a concentration-dependent manner. J Biol Chem. 2006;281(45):34696\u2013704. https:\/\/doi.org\/10.1074\/jbc.M604009200.","journal-title":"J Biol Chem"},{"issue":"28","key":"798_CR324","doi-asserted-by":"publisher","first-page":"8884","DOI":"10.1523\/jneurosci.0968-09.2009","volume":"29","author":"M Abdouh","year":"2009","unstructured":"Abdouh M, Facchino S, Chatoo W, Balasingam V, Ferreira J, Bernier G. BMI1 sustains human glioblastoma multiforme stem cell renewal. J Neurosci. 2009;29(28):8884\u201396. https:\/\/doi.org\/10.1523\/jneurosci.0968-09.2009.","journal-title":"J Neurosci"},{"issue":"2","key":"798_CR325","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/onc.2011.232","volume":"31","author":"X Wang","year":"2012","unstructured":"Wang X, Venugopal C, Manoranjan B, McFarlane N, O\u2019Farrell E, Nolte S, et al. Sonic hedgehog regulates Bmi1 in human medulloblastoma brain tumor-initiating cells. Oncogene. 2012;31(2):187\u201399. https:\/\/doi.org\/10.1038\/onc.2011.232.","journal-title":"Oncogene"},{"key":"798_CR326","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158231","author":"J Xu","year":"2022","unstructured":"Xu J, Li L, Shi P, Cui H, Yang L. The crucial roles of Bmi-1 in cancer: implications in pathogenesis, metastasis, drug resistance, and targeted therapies. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23158231.","journal-title":"Int J Mol Sci"},{"issue":"18","key":"798_CR327","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1038\/onc.2010.22","volume":"29","author":"H Ochiai","year":"2010","unstructured":"Ochiai H, Takenobu H, Nakagawa A, Yamaguchi Y, Kimura M, Ohira M, et al. Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bbeta and TSLC1 in neuroblastoma. Oncogene. 2010;29(18):2681\u201390. https:\/\/doi.org\/10.1038\/onc.2010.22.","journal-title":"Oncogene"},{"issue":"12","key":"798_CR328","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1096\/fj.11-185033","volume":"25","author":"R Huang","year":"2011","unstructured":"Huang R, Cheung NK, Vider J, Cheung IY, Gerald WL, Tickoo SK, et al. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas. FASEB J. 2011;25(12):4138\u201349. https:\/\/doi.org\/10.1096\/fj.11-185033.","journal-title":"FASEB J"},{"issue":"6","key":"798_CR329","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1093\/nar\/gkl119","volume":"34","author":"K Nowak","year":"2006","unstructured":"Nowak K, Kerl K, Fehr D, Kramps C, Gessner C, Killmer K, et al. BMI1 is a target gene of E2F\u20131 and is strongly expressed in primary neuroblastomas. Nucleic Acids Res. 2006;34(6):1745\u201354. https:\/\/doi.org\/10.1093\/nar\/gkl119.","journal-title":"Nucleic Acids Res"},{"issue":"33","key":"798_CR330","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1038\/onc.2011.536","volume":"31","author":"L Mao","year":"2012","unstructured":"Mao L, Ding J, Perdue A, Yang L, Zha Y, Ren M, et al. Cyclin E1 is a common target of BMI1 and MYCN and a prognostic marker for neuroblastoma progression. Oncogene. 2012;31(33):3785\u201395. https:\/\/doi.org\/10.1038\/onc.2011.536.","journal-title":"Oncogene"},{"issue":"6980","key":"798_CR331","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature02385","volume":"428","author":"C Leung","year":"2004","unstructured":"Leung C, Lingbeek M, Shakhova O, Liu J, Tanger E, Saremaslani P, et al. Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature. 2004;428(6980):337\u201341. https:\/\/doi.org\/10.1038\/nature02385.","journal-title":"Nature"},{"issue":"2","key":"798_CR332","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.mcn.2010.06.006","volume":"45","author":"T Subkhankulova","year":"2010","unstructured":"Subkhankulova T, Zhang X, Leung C, Marino S. Bmi1 directly represses p21Waf1\/Cip1 in Shh-induced proliferation of cerebellar granule cell progenitors. Mol Cell Neurosci. 2010;45(2):151\u201362. https:\/\/doi.org\/10.1016\/j.mcn.2010.06.006.","journal-title":"Mol Cell Neurosci"},{"key":"798_CR333","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/2051-5960-2-10","volume":"2","author":"A Merve","year":"2014","unstructured":"Merve A, Dubuc AM, Zhang X, Remke M, Baxter PA, Li XN, et al. Polycomb group gene BMI1 controls invasion of medulloblastoma cells and inhibits BMP-regulated cell adhesion. Acta Neuropathol Commun. 2014;2:10. https:\/\/doi.org\/10.1186\/2051-5960-2-10.","journal-title":"Acta Neuropathol Commun"},{"issue":"31","key":"798_CR334","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1038\/onc.2012.368","volume":"32","author":"M Calao","year":"2013","unstructured":"Calao M, Sekyere EO, Cui HJ, Cheung BB, Thomas WD, Keating J, et al. Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation. Oncogene. 2013;32(31):3616\u201326. https:\/\/doi.org\/10.1038\/onc.2012.368.","journal-title":"Oncogene"},{"issue":"5","key":"798_CR335","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41419-021-03748-y","volume":"12","author":"D Zhang","year":"2021","unstructured":"Zhang D, Huang J, Wang F, Ding H, Cui Y, Yang Y, et al. BMI1 regulates multiple myeloma-associated macrophage\u2019s pro-myeloma functions. Cell Death Dis. 2021;12(5):495. https:\/\/doi.org\/10.1038\/s41419-021-03748-y.","journal-title":"Cell Death Dis"},{"issue":"3","key":"798_CR336","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s11060-019-03192-1","volume":"143","author":"P Vora","year":"2019","unstructured":"Vora P, Seyfrid M, Venugopal C, Qazi MA, Salim S, Isserlin R, et al. Bmi1 regulates human glioblastoma stem cells through activation of differential gene networks in CD133+ brain tumor initiating cells. J Neurooncol. 2019;143(3):417\u201328. https:\/\/doi.org\/10.1007\/s11060-019-03192-1.","journal-title":"J Neurooncol"},{"issue":"5181","key":"798_CR337","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1126\/science.8091232","volume":"265","author":"H Hermeking","year":"1994","unstructured":"Hermeking H, Eick D. Mediation of c-Myc-induced apoptosis by p53. Science. 1994;265(5181):2091\u20133. https:\/\/doi.org\/10.1126\/science.8091232.","journal-title":"Science"},{"issue":"23","key":"798_CR338","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1101\/gad.8.23.2817","volume":"8","author":"AJ Wagner","year":"1994","unstructured":"Wagner AJ, Kokontis JM, Hay N. Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1\/cip1. Genes Dev. 1994;8(23):2817\u201330. https:\/\/doi.org\/10.1101\/gad.8.23.2817.","journal-title":"Genes Dev"},{"issue":"11","key":"798_CR339","first-page":"2411","volume":"11","author":"D Sakamuro","year":"1995","unstructured":"Sakamuro D, Eviner V, Elliott KJ, Showe L, White E, Prendergast GC. c-Myc induces apoptosis in epithelial cells by both p53-dependent and p53-independent mechanisms. Oncogene. 1995;11(11):2411\u20138.","journal-title":"Oncogene"},{"issue":"10","key":"798_CR340","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1038\/s41388-018-0549-9","volume":"38","author":"D Bakhshinyan","year":"2019","unstructured":"Bakhshinyan D, Venugopal C, Adile AA, Garg N, Manoranjan B, Hallett R, et al. BMI1 is a therapeutic target in recurrent medulloblastoma. Oncogene. 2019;38(10):1702\u201316. https:\/\/doi.org\/10.1038\/s41388-018-0549-9.","journal-title":"Oncogene"},{"key":"798_CR341","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13045-016-0247-4","volume":"9","author":"A Bolomsky","year":"2016","unstructured":"Bolomsky A, Schlangen K, Schreiner W, Zojer N, Ludwig H. Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment. J Hematol Oncol. 2016;9:17. https:\/\/doi.org\/10.1186\/s13045-016-0247-4.","journal-title":"J Hematol Oncol"},{"issue":"61","key":"798_CR342","doi-asserted-by":"publisher","first-page":"103731","DOI":"10.18632\/oncotarget.21909","volume":"8","author":"M Alzrigat","year":"2017","unstructured":"Alzrigat M, Parraga AA, Majumder MM, Ma A, Jin J, Osterborg A, et al. The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains. Oncotarget. 2017;8(61):103731\u201343. https:\/\/doi.org\/10.18632\/oncotarget.21909.","journal-title":"Oncotarget"},{"issue":"1","key":"798_CR343","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-06922-w","volume":"15","author":"M Hirayama","year":"2025","unstructured":"Hirayama M, Yamada E, Aoki H, Izumi K, Amano A, Toriuchi K, et al. Pharmacologic inhibition of BMI1 exerts antitumor effects against MYCN-amplified neuroblastoma, with activation of the p53 pathway. Sci Rep. 2025;15(1):22917. https:\/\/doi.org\/10.1038\/s41598-025-06922-w.","journal-title":"Sci Rep"},{"issue":"5","key":"798_CR344","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102077","volume":"6","author":"Z Qin","year":"2025","unstructured":"Qin Z, Liu S, Zheng Y, Wang Y, Chen Y, Peng X, et al. Co-targeting BMI1 and MYC to eliminate cancer stem cells in squamous cell carcinoma. Cell Rep Med. 2025;6(5):102077. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102077.","journal-title":"Cell Rep Med"},{"key":"798_CR345","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41698-019-0106-1","volume":"4","author":"A Flamier","year":"2020","unstructured":"Flamier A, Abdouh M, Hamam R, Barabino A, Patel N, Gao A, et al. Off-target effect of the BMI1 inhibitor PTC596 drives epithelial-mesenchymal transition in glioblastoma multiforme. NPJ Precis Oncol. 2020;4:1. https:\/\/doi.org\/10.1038\/s41698-019-0106-1.","journal-title":"NPJ Precis Oncol."},{"issue":"10","key":"798_CR346","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1158\/1535-7163.Mct-20-0774","volume":"20","author":"F Jernigan","year":"2021","unstructured":"Jernigan F, Branstrom A, Baird JD, Cao L, Dali M, Furia B, et al. Preclinical and early clinical development of PTC596, a novel small-molecule tubulin-binding agent. Mol Cancer Ther. 2021;20(10):1846\u201357. https:\/\/doi.org\/10.1158\/1535-7163.Mct-20-0774.","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"798_CR347","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1111\/bjh.16595","volume":"190","author":"A Bolomsky","year":"2020","unstructured":"Bolomsky A, Muller J, Stangelberger K, Lejeune M, Duray E, Breid H, et al. The anti-mitotic agents PTC-028 and PTC596 display potent activity in pre-clinical models of multiple myeloma but challenge the role of BMI-1 as an essential tumour gene. Br J Haematol. 2020;190(6):877\u201390. https:\/\/doi.org\/10.1111\/bjh.16595.","journal-title":"Br J Haematol"},{"issue":"1","key":"798_CR348","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1038\/s41598-021-81577-x","volume":"11","author":"Y Nagai","year":"2021","unstructured":"Nagai Y, Mimura N, Rizq O, Isshiki Y, Oshima M, Rizk M, et al. The combination of the tubulin binding small molecule PTC596 and proteasome inhibitors suppresses the growth of myeloma cells. Sci Rep. 2021;11(1):2074. https:\/\/doi.org\/10.1038\/s41598-021-81577-x.","journal-title":"Sci Rep"},{"issue":"18","key":"798_CR349","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1158\/1078-0432.Ccr-18-3281","volume":"25","author":"JA Eberle-Singh","year":"2019","unstructured":"Eberle-Singh JA, Sagalovskiy I, Maurer HC, Sastra SA, Palermo CF, Decker AR, et al. Effective delivery of a microtubule polymerization inhibitor synergizes with standard regimens in models of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2019;25(18):5548\u201360. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-3281.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"798_CR350","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/cpdd.904","volume":"10","author":"GI Shapiro","year":"2021","unstructured":"Shapiro GI, O\u2019Mara E, Laskin OL, Gao L, Baird JD, Spiegel RJ, et al. Pharmacokinetics and safety of PTC596, a novel tubulin-binding agent, in subjects with advanced solid tumors. Clin Pharmacol Drug Dev. 2021;10(8):940\u20139. https:\/\/doi.org\/10.1002\/cpdd.904.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"11","key":"798_CR351","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1158\/1541-7786.Mcr-20-0099","volume":"18","author":"S Senthil Kumar","year":"2020","unstructured":"Senthil Kumar S, Sengupta S, Zhu X, Mishra DK, Phoenix T, Dyer L, et al. Diffuse intrinsic pontine glioma cells are vulnerable to mitotic abnormalities associated with BMI-1 modulation. Mol Cancer Res. 2020;18(11):1711\u201323. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-20-0099.","journal-title":"Mol Cancer Res"},{"issue":"20","key":"798_CR352","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1200\/jco.23.01684","volume":"42","author":"BA Van Tine","year":"2024","unstructured":"Van Tine BA, Ingham MA, Attia S, Meyer CF, Baird JD, Brooks-Asplund E, et al. Phase Ib study of unesbulin (PTC596) plus dacarbazine for the treatment of locally recurrent, unresectable or metastatic, relapsed or refractory leiomyosarcoma. J Clin Oncol. 2024;42(20):2404\u201314. https:\/\/doi.org\/10.1200\/jco.23.01684.","journal-title":"J Clin Oncol"},{"issue":"7","key":"798_CR353","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/j.cell.2025.02.023","volume":"188","author":"ZH Gray","year":"2025","unstructured":"Gray ZH, Honer MA, Ghatalia P, Shi Y, Whetstine JR. 20 years of histone lysine demethylases: from discovery to the clinic and beyond. Cell. 2025;188(7):1747\u201383. https:\/\/doi.org\/10.1016\/j.cell.2025.02.023.","journal-title":"Cell"},{"issue":"12","key":"798_CR354","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1038\/s12276-020-00542-2","volume":"52","author":"B Perillo","year":"2020","unstructured":"Perillo B, Tramontano A, Pezone A, Migliaccio A. LSD1: more than demethylation of histone lysine residues. Exp Mol Med. 2020;52(12):1936\u201347. https:\/\/doi.org\/10.1038\/s12276-020-00542-2.","journal-title":"Exp Mol Med"},{"issue":"3","key":"798_CR355","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1248\/bpb.b18-00892","volume":"42","author":"M Nagasaka","year":"2019","unstructured":"Nagasaka M, Tsuzuki K, Ozeki Y, Tokugawa M, Ohoka N, Inoue Y, et al. Lysine-specific demethylase 1 (LSD1\/KDM1A) is a novel target gene of c-Myc. Biol Pharm Bull. 2019;42(3):481\u20138. https:\/\/doi.org\/10.1248\/bpb.b18-00892.","journal-title":"Biol Pharm Bull"},{"issue":"25","key":"798_CR356","doi-asserted-by":"publisher","first-page":"3691","DOI":"10.1038\/onc.2010.120","volume":"29","author":"S Amente","year":"2010","unstructured":"Amente S, Bertoni A, Morano A, Lania L, Avvedimento EV, Majello B. LSD1-mediated demethylation of histone H3 lysine 4 triggers Myc-induced transcription. Oncogene. 2010;29(25):3691\u2013702. https:\/\/doi.org\/10.1038\/onc.2010.120.","journal-title":"Oncogene"},{"issue":"16","key":"798_CR357","doi-asserted-by":"publisher","first-page":"14572","DOI":"10.18632\/oncotarget.3990","volume":"6","author":"S Amente","year":"2015","unstructured":"Amente S, Milazzo G, Sorrentino MC, Ambrosio S, Di Palo G, Lania L, et al. Lysine-specific demethylase (LSD1\/KDM1A) and MYCN cooperatively repress tumor suppressor genes in neuroblastoma. Oncotarget. 2015;6(16):14572\u201383. https:\/\/doi.org\/10.18632\/oncotarget.3990.","journal-title":"Oncotarget"},{"issue":"11","key":"798_CR358","doi-asserted-by":"publisher","first-page":"9907","DOI":"10.18632\/oncotarget.24035","volume":"9","author":"S Gupta","year":"2018","unstructured":"Gupta S, Doyle K, Mosbruger TL, Butterfield A, Weston A, Ast A, et al. Reversible LSD1 inhibition with HCI-2509 induces the p53 gene expression signature and disrupts the MYCN signature in high-risk neuroblastoma cells. Oncotarget. 2018;9(11):9907\u201324. https:\/\/doi.org\/10.18632\/oncotarget.24035.","journal-title":"Oncotarget"},{"issue":"48","key":"798_CR359","doi-asserted-by":"publisher","first-page":"6701","DOI":"10.1038\/onc.2017.267","volume":"36","author":"S Ambrosio","year":"2017","unstructured":"Ambrosio S, Sacc\u00e0 CD, Amente S, Paladino S, Lania L, Majello B. Lysine-specific demethylase LSD1 regulates autophagy in neuroblastoma through SESN2-dependent pathway. Oncogene. 2017;36(48):6701\u201311. https:\/\/doi.org\/10.1038\/onc.2017.267.","journal-title":"Oncogene"},{"issue":"3","key":"798_CR360","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.18632\/oncotarget.12924","volume":"8","author":"S Ambrosio","year":"2017","unstructured":"Ambrosio S, Amente S, Sacc\u00e0 CD, Capasso M, Calogero RA, Lania L, et al. LSD1 mediates MYCN control of epithelial-mesenchymal transition through silencing of metastatic suppressor NDRG1 gene. Oncotarget. 2017;8(3):3854\u201369. https:\/\/doi.org\/10.18632\/oncotarget.12924.","journal-title":"Oncotarget"},{"issue":"4","key":"798_CR361","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nm.2661","volume":"18","author":"T Schenk","year":"2012","unstructured":"Schenk T, Chen WC, G\u00f6llner S, Howell L, Jin L, Hebestreit K, et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med. 2012;18(4):605\u201311. https:\/\/doi.org\/10.1038\/nm.2661.","journal-title":"Nat Med"},{"issue":"7","key":"798_CR362","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1158\/1078-0432.Ccr-20-4054","volume":"27","author":"MM Tayari","year":"2021","unstructured":"Tayari MM, Santos HGD, Kwon D, Bradley TJ, Thomassen A, Chen C, et al. Clinical responsiveness to all-trans retinoic acid is potentiated by LSD1 inhibition and associated with a quiescent transcriptome in myeloid malignancies. Clin Cancer Res. 2021;27(7):1893\u2013903. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-4054.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"798_CR363","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1158\/0008-5472.Can-12-4300","volume":"73","author":"WL Berry","year":"2013","unstructured":"Berry WL, Janknecht R. KDM4\/JMJD2 histone demethylases: epigenetic regulators in cancer cells. Cancer Res. 2013;73(10):2936\u201342. https:\/\/doi.org\/10.1158\/0008-5472.Can-12-4300.","journal-title":"Cancer Res"},{"issue":"9","key":"798_CR364","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1038\/s41588-018-0191-z","volume":"50","author":"AD Durbin","year":"2018","unstructured":"Durbin AD, Zimmerman MW, Dharia NV, Abraham BJ, Iniguez AB, Weichert-Leahey N, et al. Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry. Nat Genet. 2018;50(9):1240\u20136. https:\/\/doi.org\/10.1038\/s41588-018-0191-z.","journal-title":"Nat Genet"},{"issue":"5","key":"798_CR365","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.cell.2014.10.024","volume":"159","author":"E Chipumuro","year":"2014","unstructured":"Chipumuro E, Marco E, Christensen CL, Kwiatkowski N, Zhang T, Hatheway CM, et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell. 2014;159(5):1126\u201339. https:\/\/doi.org\/10.1016\/j.cell.2014.10.024.","journal-title":"Cell"},{"issue":"3","key":"798_CR366","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101468","volume":"5","author":"A Abu-Zaid","year":"2024","unstructured":"Abu-Zaid A, Fang J, Jin H, Singh S, Pichavaram P, Wu Q, et al. Histone lysine demethylase 4 family proteins maintain the transcriptional program and adrenergic cellular state of MYCN-amplified neuroblastoma. Cell Rep Med. 2024;5(3):101468. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101468.","journal-title":"Cell Rep Med"},{"issue":"6","key":"798_CR367","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv080","volume":"107","author":"J Yang","year":"2015","unstructured":"Yang J, AlTahan AM, Hu D, Wang Y, Cheng PH, Morton CL, et al. The role of histone demethylase KDM4B in Myc signaling in neuroblastoma. J Natl Cancer Inst. 2015;107(6):djv080. https:\/\/doi.org\/10.1093\/jnci\/djv080.","journal-title":"J Natl Cancer Inst"},{"issue":"17","key":"798_CR368","doi-asserted-by":"publisher","first-page":"4626","DOI":"10.1158\/0008-5472.Can-16-0826","volume":"77","author":"J Yang","year":"2017","unstructured":"Yang J, Milasta S, Hu D, AlTahan AM, Interiano RB, Zhou J, et al. Targeting histone demethylases in MYC-driven neuroblastomas with ciclopirox. Cancer Res. 2017;77(17):4626\u201338. https:\/\/doi.org\/10.1158\/0008-5472.Can-16-0826.","journal-title":"Cancer Res"},{"issue":"2","key":"798_CR369","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/path.5495","volume":"252","author":"DE Tang","year":"2020","unstructured":"Tang DE, Dai Y, He JX, Lin LW, Leng QX, Geng XY, et al. Targeting the KDM4B-AR-c-Myc axis promotes sensitivity to androgen receptor-targeted therapy in advanced prostate cancer. J Pathol. 2020;252(2):101\u201313. https:\/\/doi.org\/10.1002\/path.5495.","journal-title":"J Pathol"},{"issue":"16","key":"798_CR370","doi-asserted-by":"publisher","first-page":"7779","DOI":"10.7150\/thno.58729","volume":"11","author":"MJ Wu","year":"2021","unstructured":"Wu MJ, Chen CJ, Lin TY, Liu YY, Tseng LL, Cheng ML, et al. Targeting KDM4B that coactivates c-Myc-regulated metabolism to suppress tumor growth in castration-resistant prostate cancer. Theranostics. 2021;11(16):7779\u201396. https:\/\/doi.org\/10.7150\/thno.58729.","journal-title":"Theranostics"},{"issue":"1","key":"798_CR371","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-023-01608-4","volume":"15","author":"Z Wang","year":"2023","unstructured":"Wang Z, Cai H, Li Z, Sun W, Zhao E, Cui H. Histone demethylase KDM4B accelerates the progression of glioblastoma via the epigenetic regulation of MYC stability. Clin Epigenet. 2023;15(1):192. https:\/\/doi.org\/10.1186\/s13148-023-01608-4.","journal-title":"Clin Epigenet"},{"issue":"10","key":"798_CR372","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/s41580-019-0168-5","volume":"20","author":"S Zaccara","year":"2019","unstructured":"Zaccara S, Ries RJ, Jaffrey SR. Reading, writing and erasing mRNA methylation. Nat Rev Mol Cell Biol. 2019;20(10):608\u201324. https:\/\/doi.org\/10.1038\/s41580-019-0168-5.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"798_CR373","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41568-025-00889-6","volume":"26","author":"H Luo","year":"2026","unstructured":"Luo H, Kharas MG, Jaffrey SR. N(6)-Methyladenosine: an RNA modification as a central regulator of cancer. Nat Rev Cancer. 2026;26(2):118\u201336. https:\/\/doi.org\/10.1038\/s41568-025-00889-6.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"798_CR374","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202051519","volume":"22","author":"G Wu","year":"2021","unstructured":"Wu G, Suo C, Yang Y, Shen S, Sun L, Li ST, et al. MYC promotes cancer progression by modulating m(6) A modifications to suppress target gene translation. EMBO Rep. 2021;22(3):EMBR202051519. https:\/\/doi.org\/10.15252\/embr.202051519.","journal-title":"EMBO Rep"},{"issue":"1","key":"798_CR375","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-024-03040-9","volume":"43","author":"Y Yang","year":"2024","unstructured":"Yang Y, Zhang Y, Chen G, Sun B, Luo F, Gao Y, et al. KAP1 stabilizes MYCN mRNA and promotes neuroblastoma tumorigenicity by protecting the RNA m(6)A reader YTHDC1 protein degradation. J Exp Clin Cancer Res. 2024;43(1):141. https:\/\/doi.org\/10.1186\/s13046-024-03040-9.","journal-title":"J Exp Clin Cancer Res"},{"issue":"7860","key":"798_CR376","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41586-021-03536-w","volume":"593","author":"E Yankova","year":"2021","unstructured":"Yankova E, Blackaby W, Albertella M, Rak J, De Braekeleer E, Tsagkogeorga G, et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature. 2021;593(7860):597\u2013601. https:\/\/doi.org\/10.1038\/s41586-021-03536-w.","journal-title":"Nature"},{"issue":"5","key":"798_CR377","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114165","volume":"43","author":"M Pomaville","year":"2024","unstructured":"Pomaville M, Chennakesavalu M, Wang P, Jiang Z, Sun HL, Ren P, et al. Small-molecule inhibition of the METTL3\/METTL14 complex suppresses neuroblastoma tumor growth and promotes differentiation. Cell Rep. 2024;43(5):114165. https:\/\/doi.org\/10.1016\/j.celrep.2024.114165.","journal-title":"Cell Rep"},{"issue":"10","key":"798_CR378","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1158\/2159-8290.Cd-23-0007","volume":"13","author":"AA Guirguis","year":"2023","unstructured":"Guirguis AA, Ofir-Rosenfeld Y, Knezevic K, Blackaby W, Hardick D, Chan YC, et al. Inhibition of METTL3 results in a cell-intrinsic interferon response that enhances antitumor immunity. Cancer Discov. 2023;13(10):2228\u201347. https:\/\/doi.org\/10.1158\/2159-8290.Cd-23-0007.","journal-title":"Cancer Discov"},{"issue":"4","key":"798_CR379","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ccell.2019.03.006","volume":"35","author":"Y Huang","year":"2019","unstructured":"Huang Y, Su R, Sheng Y, Dong L, Dong Z, Xu H, et al. Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia. Cancer Cell. 2019;35(4):677-91.e10. https:\/\/doi.org\/10.1016\/j.ccell.2019.03.006.","journal-title":"Cancer Cell"},{"key":"798_CR380","doi-asserted-by":"publisher","DOI":"10.3389\/fddsv.2024.1465222","author":"H Zhang","year":"2024","unstructured":"Zhang H, Wang X, Chen J, Su R. Combating cancer stem cells: RNA m6A methylation and small-molecule drug discovery. Front Drug Discov. 2024. https:\/\/doi.org\/10.3389\/fddsv.2024.1465222.","journal-title":"Front Drug Discov."},{"key":"798_CR381","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115938","volume":"263","author":"E Shirbhate","year":"2024","unstructured":"Shirbhate E, Singh V, Jahoriya V, Mishra A, Veerasamy R, Tiwari AK, et al. Dual inhibitors of HDAC and other epigenetic regulators: a novel strategy for cancer treatment. Eur J Med Chem. 2024;263:115938. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115938.","journal-title":"Eur J Med Chem"},{"key":"798_CR382","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.117235","volume":"285","author":"H Liang","year":"2025","unstructured":"Liang H, Li S, Peng X, Xiao H. Overview of the epigenetic\/cytotoxic dual-target inhibitors for cancer therapy. Eur J Med Chem. 2025;285:117235. https:\/\/doi.org\/10.1016\/j.ejmech.2024.117235.","journal-title":"Eur J Med Chem"},{"issue":"1","key":"798_CR383","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15424","volume":"8","author":"E San Jos\u00e9-En\u00e9riz","year":"2017","unstructured":"San Jos\u00e9-En\u00e9riz E, Agirre X, Rabal O, Vilas-Zornoza A, Sanchez-Arias JA, Miranda E, et al. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies. Nat Commun. 2017;8(1):15424. https:\/\/doi.org\/10.1038\/ncomms15424.","journal-title":"Nat Commun"},{"key":"798_CR384","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112868","volume":"209","author":"J Chen","year":"2021","unstructured":"Chen J, Li Y, Zhang J, Zhang M, Wei A, Liu H, et al. Discovery of selective HDAC\/BRD4 dual inhibitors as epigenetic probes. Eur J Med Chem. 2021;209:112868. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112868.","journal-title":"Eur J Med Chem"},{"issue":"1","key":"798_CR385","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41420-025-02470-4","volume":"11","author":"P Gou","year":"2025","unstructured":"Gou P, Fang C, Xu M, Zhang D, Wu X, Zhang L, et al. The dual HDAC\/PI3K inhibitor CUDC-907 inhibits the growth and proliferation of MYC-driven group 3 medulloblastoma. Cell Death Discov. 2025;11(1):172. https:\/\/doi.org\/10.1038\/s41420-025-02470-4.","journal-title":"Cell Death Discov."},{"issue":"5","key":"798_CR386","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.3324\/haematol.2019.233445","volume":"106","author":"X Li","year":"2021","unstructured":"Li X, Su Y, Hege K, Madlambayan G, Edwards H, Knight T, et al. The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia. Haematologica. 2021;106(5):1262\u201377. https:\/\/doi.org\/10.3324\/haematol.2019.233445.","journal-title":"Haematologica"},{"issue":"1","key":"798_CR387","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-01909-7","volume":"40","author":"M Hirano","year":"2021","unstructured":"Hirano M, Imai Y, Kaito Y, Murayama T, Sato K, Ishida T, et al. Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma. J Exp Clin Cancer Res. 2021;40(1):110. https:\/\/doi.org\/10.1186\/s13046-021-01909-7.","journal-title":"J Exp Clin Cancer Res"},{"key":"798_CR388","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14041067","author":"R Chilamakuri","year":"2022","unstructured":"Chilamakuri R, Agarwal S. Dual targeting of PI3K and HDAC by CUDC-907 inhibits pediatric neuroblastoma growth. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14041067.","journal-title":"Cancers (Basel)."},{"issue":"5","key":"798_CR389","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1021\/jm901453q","volume":"53","author":"X Cai","year":"2010","unstructured":"Cai X, Zhai HX, Wang J, Forrester J, Qu H, Yin L, et al. Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer. J Med Chem. 2010;53(5):2000\u20139. https:\/\/doi.org\/10.1021\/jm901453q.","journal-title":"J Med Chem"},{"issue":"19","key":"798_CR390","doi-asserted-by":"publisher","first-page":"5032","DOI":"10.1158\/1078-0432.Ccr-14-0570","volume":"20","author":"T Shimizu","year":"2014","unstructured":"Shimizu T, LoRusso PM, Papadopoulos KP, Patnaik A, Beeram M, Smith LS, et al. Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors. Clin Cancer Res. 2014;20(19):5032\u201340. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-0570.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"798_CR391","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1158\/1078-0432.Ccr-14-2820","volume":"21","author":"TJ Galloway","year":"2015","unstructured":"Galloway TJ, Wirth LJ, Colevas AD, Gilbert J, Bauman JE, Saba NF, et al. A phase I study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with head and neck squamous cell carcinoma. Clin Cancer Res. 2015;21(7):1566\u201373. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-2820.","journal-title":"Clin Cancer Res"},{"issue":"24","key":"798_CR392","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.1128\/MCB.06120-11","volume":"31","author":"J Fan","year":"2011","unstructured":"Fan J, Hitosugi T, Chung T-W, Xie J, Ge Q, Gu T-L, et al. Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH\/NAD+ redox homeostasis in cancer cells. Mol Cell Biol. 2011;31(24):4938\u201350. https:\/\/doi.org\/10.1128\/MCB.06120-11.","journal-title":"Mol Cell Biol"},{"issue":"4","key":"798_CR393","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1023\/A:1022446730452","volume":"29","author":"CV Dang","year":"1997","unstructured":"Dang CV, Lewis BC, Dolde C, Dang G, Shim H. Oncogenes in tumor metabolism, tumorigenesis, and apoptosis. J Bioenerg Biomembr. 1997;29(4):345\u201354. https:\/\/doi.org\/10.1023\/A:1022446730452.","journal-title":"J Bioenerg Biomembr"},{"issue":"5","key":"798_CR394","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1073\/pnas.0914433107","volume":"107","author":"A Le","year":"2010","unstructured":"Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci USA. 2010;107(5):2037\u201342. https:\/\/doi.org\/10.1073\/pnas.0914433107.","journal-title":"Proc Natl Acad Sci USA"},{"key":"798_CR395","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116598","volume":"275","author":"H Sharma","year":"2024","unstructured":"Sharma H, Mondal S, Urquiza U, Esparza C, Bartlett S, Santa-Pinter L, et al. Synthesis and biological characterization of an orally bioavailable lactate dehydrogenase-A inhibitor against pancreatic cancer. Eur J Med Chem. 2024;275:116598. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116598.","journal-title":"Eur J Med Chem"},{"issue":"7","key":"798_CR396","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.3324\/haematol.2016.163030","volume":"102","author":"RA Noble","year":"2017","unstructured":"Noble RA, Bell N, Blair H, Sikka A, Thomas H, Phillips N, et al. Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma. Haematologica. 2017;102(7):1247\u201357. https:\/\/doi.org\/10.3324\/haematol.2016.163030.","journal-title":"Haematologica"},{"issue":"21","key":"798_CR397","doi-asserted-by":"publisher","first-page":"7381","DOI":"10.1128\/MCB.00440-07","volume":"27","author":"J-w Kim","year":"2007","unstructured":"Kim J-w, Gao P, Liu Y-C, Semenza GL, Dang CV. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol. 2007;27(21):7381\u201393. https:\/\/doi.org\/10.1128\/MCB.00440-07.","journal-title":"Mol Cell Biol"},{"issue":"3","key":"798_CR398","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1007\/s10637-013-0047-4","volume":"32","author":"EM Dunbar","year":"2014","unstructured":"Dunbar EM, Coats BS, Shroads AL, Langaee T, Lew A, Forder JR, et al. Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors. Investig New Drugs. 2014;32(3):452\u201364. https:\/\/doi.org\/10.1007\/s10637-013-0047-4.","journal-title":"Investig New Drugs"},{"issue":"3","key":"798_CR399","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1007\/s10637-022-01235-5","volume":"40","author":"SF Powell","year":"2022","unstructured":"Powell SF, Mazurczak M, Dib EG, Bleeker JS, Geeraerts LH, Tinguely M, et al. Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell carcinoma. Investig New Drugs. 2022;40(3):622\u201333. https:\/\/doi.org\/10.1007\/s10637-022-01235-5.","journal-title":"Investig New Drugs"},{"issue":"4","key":"798_CR400","doi-asserted-by":"publisher","DOI":"10.1002\/exp.20240031","volume":"5","author":"A Deng","year":"2025","unstructured":"Deng A, Fan R, Gou J, Sang R, Lin R, Zhao T, et al. Innovative PDK1-degrading PROTACs transform cancer aerobic glycolysis and induce immunogenic cell death in breast cancer. Exploration (Beijing). 2025;5(4):e20240031. https:\/\/doi.org\/10.1002\/exp.20240031.","journal-title":"Exploration (Beijing)."},{"issue":"20","key":"798_CR401","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1002\/cmdc.201600276","volume":"11","author":"H Siebeneicher","year":"2016","unstructured":"Siebeneicher H, Cleve A, Rehwinkel H, Neuhaus R, Heisler I, M\u00fcller T, et al. Identification and optimization of the first highly selective GLUT1 inhibitor BAY-876. ChemMedChem. 2016;11(20):2261\u201371. https:\/\/doi.org\/10.1002\/cmdc.201600276.","journal-title":"ChemMedChem"},{"issue":"8","key":"798_CR402","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1158\/1535-7163.Mct-12-0131","volume":"11","author":"Y Liu","year":"2012","unstructured":"Liu Y, Cao Y, Zhang W, Bergmeier S, Qian Y, Akbar H, et al. A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther. 2012;11(8):1672\u201382. https:\/\/doi.org\/10.1158\/1535-7163.Mct-12-0131.","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"798_CR403","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0163768","volume":"11","author":"W Zhu","year":"2016","unstructured":"Zhu W, Ye L, Zhang J, Yu P, Wang H, Ye Z, et al. PFK15, a small molecule inhibitor of PFKFB3, induces cell cycle arrest, apoptosis and inhibits invasion in gastric cancer. PLoS\u00a0One. 2016;11(9):e0163768. https:\/\/doi.org\/10.1371\/journal.pone.0163768.","journal-title":"PLoS\u00a0One"},{"key":"798_CR404","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.isci.2019.10.020","volume":"21","author":"G Oliynyk","year":"2019","unstructured":"Oliynyk G, Ruiz-P\u00e9rez MV, Sainero-Alcolado L, Dzieran J, Zirath H, Gallart-Ayala H, et al. MYCN-enhanced oxidative and glycolytic metabolism reveals vulnerabilities for targeting neuroblastoma. iScience. 2019;21:188\u2013204. https:\/\/doi.org\/10.1016\/j.isci.2019.10.020.","journal-title":"iScience"},{"key":"798_CR405","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.102128","author":"MV Ruiz-P\u00e9rez","year":"2021","unstructured":"Ruiz-P\u00e9rez MV, Sainero-Alcolado L, Oliynyk G, Matuschek I, Balboni N, Ubhayasekera SJKA, et al. Inhibition of fatty acid synthesis induces differentiation and reduces tumor burden in childhood neuroblastoma. iScience. 2021. https:\/\/doi.org\/10.1016\/j.isci.2021.102128.","journal-title":"iScience"},{"issue":"25","key":"798_CR406","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2427211122","volume":"122","author":"J Lia\u00f1o-Pons","year":"2025","unstructured":"Lia\u00f1o-Pons J, Garde-Lapido E, Fahrig FL, J\u00e4ckering M, Yuan Y, Andersson S, et al. Combined targeting of PRDX6 and GSTP1 as a potential differentiation strategy for neuroblastoma treatment. Proc Natl Acad Sci. 2025;122(25):e2427211122. https:\/\/doi.org\/10.1073\/pnas.2427211122.","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"798_CR407","doi-asserted-by":"publisher","first-page":"3728","DOI":"10.1038\/s41467-022-31331-2","volume":"13","author":"L Tao","year":"2022","unstructured":"Tao L, Mohammad MA, Milazzo G, Moreno-Smith M, Patel TD, Zorman B, et al. MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma. Nat Commun. 2022;13(1):3728. https:\/\/doi.org\/10.1038\/s41467-022-31331-2.","journal-title":"Nat Commun"},{"issue":"3","key":"798_CR408","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.cmet.2019.07.012","volume":"30","author":"AM Gouw","year":"2019","unstructured":"Gouw AM, Margulis K, Liu NS, Raman SJ, Mancuso A, Toal GG, et al. The MYC oncogene cooperates with sterol-regulated element-binding protein to regulate lipogenesis essential for neoplastic growth. Cell Metab. 2019;30(3):556-72.e5. https:\/\/doi.org\/10.1016\/j.cmet.2019.07.012.","journal-title":"Cell Metab"},{"issue":"4","key":"798_CR409","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nm.4055","volume":"22","author":"R Camarda","year":"2016","unstructured":"Camarda R, Zhou AY, Kohnz RA, Balakrishnan S, Mahieu C, Anderton B, et al. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nat Med. 2016;22(4):427\u201332. https:\/\/doi.org\/10.1038\/nm.4055.","journal-title":"Nat Med"},{"issue":"1","key":"798_CR410","doi-asserted-by":"publisher","first-page":"7438","DOI":"10.1038\/s41467-025-62486-3","volume":"16","author":"J Williams","year":"2025","unstructured":"Williams J, Camarda R, Malkov S, Zimmerman LJ, Manning S, Aran D, et al. Tumor cell-adipocyte gap junctions activate lipolysis and contribute to breast tumorigenesis. Nat Commun. 2025;16(1):7438. https:\/\/doi.org\/10.1038\/s41467-025-62486-3.","journal-title":"Nat Commun"},{"issue":"8","key":"798_CR411","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.tibs.2010.05.003","volume":"35","author":"DR Wise","year":"2010","unstructured":"Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci. 2010;35(8):427\u201333. https:\/\/doi.org\/10.1016\/j.tibs.2010.05.003.","journal-title":"Trends Biochem Sci"},{"issue":"48","key":"798_CR412","doi-asserted-by":"publisher","first-page":"18782","DOI":"10.1073\/pnas.0810199105","volume":"105","author":"DR Wise","year":"2008","unstructured":"Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang X-Y, Pfeiffer HK, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci. 2008;105(48):18782\u20137. https:\/\/doi.org\/10.1073\/pnas.0810199105.","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"798_CR413","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1083\/jcb.200703099","volume":"178","author":"M Yuneva","year":"2007","unstructured":"Yuneva M, Zamboni N, Oefner P, Sachidanandam R, Lazebnik Y. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol. 2007;178(1):93\u2013105. https:\/\/doi.org\/10.1083\/jcb.200703099.","journal-title":"J Cell Biol"},{"key":"798_CR414","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1101\/sqb.2011.76.011296","volume":"76","author":"CV Dang","year":"2011","unstructured":"Dang CV. Therapeutic targeting of Myc-reprogrammed cancer cell metabolism. Cold Spring Harb Symp Quant Biol. 2011;76:369\u201374. https:\/\/doi.org\/10.1101\/sqb.2011.76.011296.","journal-title":"Cold Spring Harb Symp Quant Biol"},{"issue":"3","key":"798_CR415","doi-asserted-by":"publisher","DOI":"10.1111\/acel.12947","volume":"18","author":"X Zhao","year":"2019","unstructured":"Zhao X, Petrashen AP, Sanders JA, Peterson AL, Sedivy JM. SLC1A5 glutamine transporter is a target of MYC and mediates reduced mTORC1 signaling and increased fatty acid oxidation in long-lived Myc hypomorphic mice. Aging Cell. 2019;18(3):e12947. https:\/\/doi.org\/10.1111\/acel.12947.","journal-title":"Aging Cell"},{"issue":"21","key":"798_CR416","doi-asserted-by":"publisher","first-page":"6479","DOI":"10.1158\/1078-0432.Ccr-09-0889","volume":"15","author":"CV Dang","year":"2009","unstructured":"Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res. 2009;15(21):6479\u201383. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-09-0889.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"798_CR417","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/BF00170760","volume":"3","author":"A Rahman","year":"1985","unstructured":"Rahman A, Smith FP, Luc P-VT, Woolley PV. Phase I study and clinical pharmacology of 6-diazo-5-oxo-L-norleucine (DON). Investig New Drugs. 1985;3(4):369\u201374. https:\/\/doi.org\/10.1007\/BF00170760.","journal-title":"Investig New Drugs."},{"issue":"6468","key":"798_CR418","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1126\/science.aav2588","volume":"366","author":"RD Leone","year":"2019","unstructured":"Leone RD, Zhao L, Englert JM, Sun I-M, Oh M-H, Sun I-H, et al. Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. Science. 2019;366(6468):1013\u201321. https:\/\/doi.org\/10.1126\/science.aav2588.","journal-title":"Science"},{"issue":"10","key":"798_CR419","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/j.tranon.2019.05.013","volume":"12","author":"AR Hanaford","year":"2019","unstructured":"Hanaford AR, Alt J, Rais R, Wang SZ, Kaur H, Thorek DLJ, et al. Orally bioavailable glutamine antagonist prodrug JHU-083 penetrates mouse brain and suppresses the growth of MYC-driven medulloblastoma. Transl Oncol. 2019;12(10):1314\u201322. https:\/\/doi.org\/10.1016\/j.tranon.2019.05.013.","journal-title":"Transl Oncol"},{"issue":"23","key":"798_CR420","doi-asserted-by":"publisher","first-page":"10551","DOI":"10.1021\/jm301191p","volume":"55","author":"K Shukla","year":"2012","unstructured":"Shukla K, Ferraris DV, Thomas AG, Stathis M, Duvall B, Delahanty G, et al. Design, synthesis, and pharmacological evaluation of Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. J Med Chem. 2012;55(23):10551\u201363. https:\/\/doi.org\/10.1021\/jm301191p.","journal-title":"J Med Chem"},{"issue":"10","key":"798_CR421","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1038\/s43018-024-00811-3","volume":"5","author":"CD DiNardo","year":"2024","unstructured":"DiNardo CD, Verma D, Baran N, Bhagat TD, Skwarska A, Lodi A, et al. Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b\/2 clinical trial and correlative analyses. Nat Cancer Inst Monogr. 2024;5(10):1515\u201333. https:\/\/doi.org\/10.1038\/s43018-024-00811-3.","journal-title":"Nat Cancer Inst Monogr"},{"issue":"1","key":"798_CR422","doi-asserted-by":"publisher","first-page":"9690","DOI":"10.1038\/s41467-025-64730-2","volume":"16","author":"Y Sung","year":"2025","unstructured":"Sung Y, Yu YC, Lee M, Lim S, Lee Y, Kang M, et al. Targeting cancer glutamine dependency with a first-in-class inhibitor of the mitochondrial glutamine transporter SLC1A5_var. Nat Commun. 2025;16(1):9690. https:\/\/doi.org\/10.1038\/s41467-025-64730-2.","journal-title":"Nat Commun"},{"issue":"14","key":"798_CR423","doi-asserted-by":"publisher","first-page":"6225","DOI":"10.1128\/MCB.25.14.6225-6234.2005","volume":"25","author":"F Li","year":"2005","unstructured":"Li F, Wang Y, Zeller KI, Potter JJ, Wonsey DR, O\u2019Donnell KA, et al. Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol Cell Biol. 2005;25(14):6225\u201334. https:\/\/doi.org\/10.1128\/MCB.25.14.6225-6234.2005.","journal-title":"Mol Cell Biol"},{"key":"798_CR424","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.semcdb.2015.08.003","volume":"43","author":"AL Hsieh","year":"2015","unstructured":"Hsieh AL, Walton ZE, Altman BJ, Stine ZE, Dang CV. MYC and metabolism on the path to cancer. Semin Cell Dev Biol. 2015;43:11\u201321. https:\/\/doi.org\/10.1016\/j.semcdb.2015.08.003.","journal-title":"Semin Cell Dev Biol"},{"key":"798_CR425","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116180","author":"GA Lueg","year":"2025","unstructured":"Lueg GA, Zhang J, Faronato M, Gorelik A, Kallemeijn WW, Falciani F, et al. MYC deregulation sensitizes cancer cells to N-myristoyltransferase inhibition. Cell Rep. 2025. https:\/\/doi.org\/10.1016\/j.celrep.2025.116180.","journal-title":"Cell Rep"},{"issue":"11","key":"798_CR426","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06278-x","volume":"14","author":"K Borankova","year":"2023","unstructured":"Borankova K, Krchniakova M, Leck LYW, Kubistova A, Neradil J, Jansson PJ, et al. Mitoribosomal synthetic lethality overcomes multidrug resistance in MYC-driven neuroblastoma. Cell Death Dis. 2023;14(11):747. https:\/\/doi.org\/10.1038\/s41419-023-06278-x.","journal-title":"Cell Death Dis"},{"issue":"4","key":"798_CR427","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s43018-022-00355-4","volume":"3","author":"H Alborzinia","year":"2022","unstructured":"Alborzinia H, Fl\u00f3rez AF, Kreth S, Br\u00fcckner LM, Yildiz U, Gartlgruber M, et al. MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis. Nat Cancer. 2022;3(4):471\u201385. https:\/\/doi.org\/10.1038\/s43018-022-00355-4.","journal-title":"Nat Cancer"},{"issue":"1","key":"798_CR428","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47868-3","volume":"15","author":"N Venkateswaran","year":"2024","unstructured":"Venkateswaran N, Garcia R, Lafita-Navarro MC, Hao Y-H, Perez-Castro L, Nogueira PAS, et al. Tryptophan fuels MYC-dependent liver tumorigenesis through indole 3-pyruvate synthesis. Nat Commun. 2024;15(1):4266. https:\/\/doi.org\/10.1038\/s41467-024-47868-3.","journal-title":"Nat Commun"},{"issue":"11","key":"798_CR429","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1038\/s42255-023-00915-7","volume":"5","author":"P Kreuzaler","year":"2023","unstructured":"Kreuzaler P, Inglese P, Ghanate A, Gjelaj E, Wu V, Panina Y, et al. Vitamin B5 supports MYC oncogenic metabolism and tumor progression in breast cancer. Nat Metab. 2023;5(11):1870\u201386. https:\/\/doi.org\/10.1038\/s42255-023-00915-7.","journal-title":"Nat Metab"},{"issue":"6","key":"798_CR430","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41419-024-06821-4","volume":"15","author":"Y Li","year":"2024","unstructured":"Li Y, Song Y, Shi Z, Hou H, Yu Y, Pan F, et al. Syrosingopine and UK5099 synergistically suppress non-small cell lung cancer by activating the integrated stress response. Cell Death Dis. 2024;15(6):431. https:\/\/doi.org\/10.1038\/s41419-024-06821-4.","journal-title":"Cell Death Dis"},{"issue":"2","key":"798_CR431","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/path.6066","volume":"260","author":"A Van der Vreken","year":"2023","unstructured":"Van der Vreken A, Oudaert I, Ates G, Faict S, Vlummens P, Satilmis H, et al. Metformin confers sensitisation to syrosingopine in multiple myeloma cells by metabolic blockage and inhibition of protein synthesis. J Pathol. 2023;260(2):112\u201323. https:\/\/doi.org\/10.1002\/path.6066.","journal-title":"J Pathol"},{"issue":"7354","key":"798_CR432","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature10189","volume":"475","author":"GM DeNicola","year":"2011","unstructured":"DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 2011;475(7354):106\u20139. https:\/\/doi.org\/10.1038\/nature10189.","journal-title":"Nature"},{"issue":"3","key":"798_CR433","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.ymthe.2022.12.011","volume":"31","author":"PV Raninga","year":"2023","unstructured":"Raninga PV, He Y, Datta KK, Lu X, Maheshwari UR, Venkat P, et al. Combined thioredoxin reductase and glutaminase inhibition exerts synergistic anti-tumor activity in MYC-high high-grade serous ovarian carcinoma. Mol Ther. 2023;31(3):729\u201343. https:\/\/doi.org\/10.1016\/j.ymthe.2022.12.011.","journal-title":"Mol Ther"},{"issue":"4","key":"798_CR434","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.4049\/jimmunol.1402382","volume":"194","author":"JM God","year":"2015","unstructured":"God JM, Cameron C, Figueroa J, Amria S, Hossain A, Kempkes B, et al. Elevation of c-MYC disrupts HLA class II\u2013mediated immune recognition of human B cell tumors. J Immunol. 2015;194(4):1434\u201345. https:\/\/doi.org\/10.4049\/jimmunol.1402382.","journal-title":"J Immunol"},{"issue":"5","key":"798_CR435","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/0092-8674(86)90509-x","volume":"47","author":"R Bernards","year":"1986","unstructured":"Bernards R, Dessain SK, Weinberg RA. N-myc amplification causes down-modulation of MHC class I antigen expression in neuroblastoma. Cell. 1986;47(5):667\u201374. https:\/\/doi.org\/10.1016\/0092-8674(86)90509-x.","journal-title":"Cell"},{"issue":"10","key":"798_CR436","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41568-019-0183-z","volume":"19","author":"M Feng","year":"2019","unstructured":"Feng M, Jiang W, Kim BYS, Zhang CC, Fu Y-X, Weissman IL. Phagocytosis checkpoints as new targets for cancer immunotherapy. Nat Rev Cancer. 2019;19(10):568\u201386. https:\/\/doi.org\/10.1038\/s41568-019-0183-z.","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"798_CR437","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/nm1649","volume":"13","author":"L Soucek","year":"2007","unstructured":"Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med. 2007;13(10):1211\u20138. https:\/\/doi.org\/10.1038\/nm1649.","journal-title":"Nat Med"},{"key":"798_CR438","doi-asserted-by":"publisher","DOI":"10.64898\/2026.02.24.707647","author":"T Campos","year":"2026","unstructured":"Campos T, Kortlever R, Sodir N, Buck M, Stockis J, Parker J, et al. Myc inhibition triggers GM-CSF-driven regression of pancreatic tumours. bioRxiv. 2026. https:\/\/doi.org\/10.64898\/2026.02.24.707647.","journal-title":"bioRxiv."},{"issue":"1","key":"798_CR439","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34000-6","volume":"13","author":"D Zimmerli","year":"2022","unstructured":"Zimmerli D, Brambillasca CS, Talens F, Bhin J, Linstra R, Romanens L, et al. MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling. Nat Commun. 2022;13(1):6579. https:\/\/doi.org\/10.1038\/s41467-022-34000-6.","journal-title":"Nat Commun"},{"issue":"4","key":"798_CR440","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1158\/0008-5472.Can-22-0232","volume":"83","author":"R Dhanasekaran","year":"2023","unstructured":"Dhanasekaran R, Hansen AS, Park J, Lemaitre L, Lai I, Adeniji N, et al. MYC overexpression drives immune evasion in hepatocellular carcinoma that is reversible through restoration of proinflammatory macrophages. Cancer Res. 2023;83(4):626\u201340. https:\/\/doi.org\/10.1158\/0008-5472.Can-22-0232.","journal-title":"Cancer Res"},{"key":"798_CR441","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.50731","volume":"9","author":"R Dhanasekaran","year":"2020","unstructured":"Dhanasekaran R, Baylot V, Kim M, Kuruvilla S, Bellovin DI, Adeniji N, et al. MYC and Twist1 cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunity. Elife. 2020;9:e50731. https:\/\/doi.org\/10.7554\/eLife.50731.","journal-title":"Elife"},{"key":"798_CR442","doi-asserted-by":"publisher","DOI":"10.64898\/2026.02.06.704498","author":"RM Kortlever","year":"2026","unstructured":"Kortlever RM, Campos T, Boeing S, Uzwyshyn-Jones K, Perfetto A, Evan GI. Targeting Myc activates a tissue-specific tumour resolution programme. bioRxiv. 2026. https:\/\/doi.org\/10.64898\/2026.02.06.704498.","journal-title":"bioRxiv."},{"issue":"12","key":"798_CR443","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41577-021-00541-y","volume":"21","author":"K DePeaux","year":"2021","unstructured":"DePeaux K, Delgoffe GM. Metabolic barriers to cancer immunotherapy. Nat Rev Immunol. 2021;21(12):785\u201397. https:\/\/doi.org\/10.1038\/s41577-021-00541-y.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"798_CR444","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s12195-020-00652-x","volume":"13","author":"R Sangsuwan","year":"2020","unstructured":"Sangsuwan R, Thuamsang B, Pacifici N, Allen R, Han H, Miakicheva S, et al. Lactate exposure promotes immunosuppressive phenotypes in innate immune cells. Cell Mol Bioeng. 2020;13(5):541\u201357. https:\/\/doi.org\/10.1007\/s12195-020-00652-x.","journal-title":"Cell Mol Bioeng"},{"issue":"3","key":"798_CR445","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.4049\/jimmunol.1202702","volume":"191","author":"Z Husain","year":"2013","unstructured":"Husain Z, Huang Y, Seth P, Sukhatme VP. Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells. J Immunol. 2013;191(3):1486\u201395. https:\/\/doi.org\/10.4049\/jimmunol.1202702.","journal-title":"J Immunol"},{"issue":"42","key":"798_CR446","doi-asserted-by":"publisher","first-page":"5829","DOI":"10.1038\/onc.2017.188","volume":"36","author":"J Feng","year":"2017","unstructured":"Feng J, Yang H, Zhang Y, Wei H, Zhu Z, Zhu B, et al. Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells. Oncogene. 2017;36(42):5829\u201339. https:\/\/doi.org\/10.1038\/onc.2017.188.","journal-title":"Oncogene"},{"issue":"7851","key":"798_CR447","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41586-020-03045-2","volume":"591","author":"MJ Watson","year":"2021","unstructured":"Watson MJ, Vignali PDA, Mullett SJ, Overacre-Delgoffe AE, Peralta RM, Grebinoski S, et al. Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. Nature. 2021;591(7851):645\u201351. https:\/\/doi.org\/10.1038\/s41586-020-03045-2.","journal-title":"Nature"},{"issue":"21","key":"798_CR448","doi-asserted-by":"publisher","first-page":"5435","DOI":"10.1158\/0008-5472.Can-12-0569","volume":"72","author":"M Platten","year":"2012","unstructured":"Platten M, Wick W, Van den Eynde BJ. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res. 2012;72(21):5435\u201340. https:\/\/doi.org\/10.1158\/0008-5472.Can-12-0569.","journal-title":"Cancer Res"},{"issue":"1","key":"798_CR449","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0644-y","volume":"11","author":"M Liu","year":"2018","unstructured":"Liu M, Wang X, Wang L, Ma X, Gong Z, Zhang S, et al. Targeting the IDO1 pathway in cancer: from bench to bedside. J Hematol Oncol. 2018;11(1):100. https:\/\/doi.org\/10.1186\/s13045-018-0644-y.","journal-title":"J Hematol Oncol"},{"key":"798_CR450","doi-asserted-by":"publisher","DOI":"10.1172\/jci178540","author":"L Pang","year":"2024","unstructured":"Pang L, Zhou F, Liu Y, Ali H, Khan F, Heimberger AB, et al. Epigenetic regulation of tumor immunity. J Clin Investig. 2024. https:\/\/doi.org\/10.1172\/jci178540.","journal-title":"J Clin Investig"},{"issue":"1","key":"798_CR451","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-021-01100-x","volume":"13","author":"JD Licht","year":"2021","unstructured":"Licht JD, Bennett RL. Leveraging epigenetics to enhance the efficacy of immunotherapy. Clin Epigenet. 2021;13(1):115. https:\/\/doi.org\/10.1186\/s13148-021-01100-x.","journal-title":"Clin Epigenet"},{"key":"798_CR452","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2102358119","author":"AJ Wolpaw","year":"2022","unstructured":"Wolpaw AJ, Grossmann LD, Dessau JL, Dong MM, Aaron BJ, Brafford PA, et al. Epigenetic state determines inflammatory sensing in neuroblastoma. Proc Natl Acad Sci USA. 2022. https:\/\/doi.org\/10.1073\/pnas.2102358119.","journal-title":"Proc Natl Acad Sci USA"},{"key":"798_CR453","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001335","author":"JA Seier","year":"2021","unstructured":"Seier JA, Reinhardt J, Saraf K, Ng SS, Layer JP, Corvino D, et al. Druggable epigenetic suppression of interferon-induced chemokine expression linked to MYCN amplification in neuroblastoma. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2020-001335.","journal-title":"J Immunother Cancer"},{"key":"798_CR454","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005002","author":"AM Cornel","year":"2022","unstructured":"Cornel AM, Dunnebach E, Hofman DA, Das S, Sengupta S, van den Ham F, et al. Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2022-005002.","journal-title":"J Immunother Cancer"},{"issue":"7","key":"798_CR455","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1158\/2326-6066.Cir-21-0826","volume":"10","author":"KM Lee","year":"2022","unstructured":"Lee KM, Lin CC, Servetto A, Bae J, Kandagatla V, Ye D, et al. Epigenetic repression of STING by MYC promotes immune evasion and resistance to immune checkpoint inhibitors in triple-negative breast cancer. Cancer Immunol Res. 2022;10(7):829\u201343. https:\/\/doi.org\/10.1158\/2326-6066.Cir-21-0826.","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"798_CR456","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.cell.2017.10.022","volume":"171","author":"MJ Topper","year":"2017","unstructured":"Topper MJ, Vaz M, Chiappinelli KB, DeStefano Shields CE, Niknafs N, Yen RC, et al. Epigenetic therapy ties MYC depletion to reversing immune evasion and treating lung cancer. Cell. 2017;171(6):1284-300.e21. https:\/\/doi.org\/10.1016\/j.cell.2017.10.022.","journal-title":"Cell"},{"issue":"4","key":"798_CR457","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.chembiol.2023.09.001","volume":"31","author":"H Yu","year":"2024","unstructured":"Yu H, Liu J, Bu X, Ma Z, Yao Y, Li J, et al. Targeting METTL3 reprograms the tumor microenvironment to improve cancer immunotherapy. Cell Chem Biol. 2024;31(4):776-91.e7. https:\/\/doi.org\/10.1016\/j.chembiol.2023.09.001.","journal-title":"Cell Chem Biol"},{"key":"798_CR458","doi-asserted-by":"publisher","unstructured":"Zirath H, Frenzel A, Oliynyk G, Segerstr\u00f6m L, Westermark UK, Larsson K, et al. MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells. Proc Natl Acad Sci U S A . 2013;110(25):10258\u201363. https:\/\/doi.org\/10.1073\/pnas.1222404110","DOI":"10.1073\/pnas.1222404110"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00798-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-026-00798-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00798-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:02:46Z","timestamp":1789390966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-026-00798-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":458,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["798"],"URL":"https:\/\/doi.org\/10.1007\/s40259-026-00798-6","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"27 June 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Lourdes Sainero-Alcolado (LSA), Dilraj Lama (DL), Mohammad Alzrigat (MA), and Marie Arsenian-Henriksson (MAH) declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not\u00a0applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to\u00a0Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not\u00a0applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Availability of Data and Material:","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not\u00a0applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LSA, DL, and MA wrote the manuscript with input from MAH. LSA, DL, and MA made the Figures. MAH contributed to manuscript design and revision. All authors approved the final version.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No datasets were generated or analyzed during the current study.","order":8,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}